The Journal of Clinical Psychiatry

Subject Index to Volume 66: January 2005 Through December 2005

Academic Highlights
Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. June 790–798
Optimizing pharmacotherapy to maximize outcome in schizophrenia. Jan 122–133
Focus on bipolar disorder treatment. Dec 1598–1609
Untangling depression and anxiety: clinical challenges. Nov 1477–1487
Adjunctive Therapy see Drug Therapy, Combination
Adolescents
Clinical differences between suicidal and nonsuicidal depressed children and adolescents. Barbe, Apr 492–498
Excessive daytime sleepiness in young adults: a 20-year prospective community study. Hasler, Apr 521–529
Introduction. Developmental neurobiology and psychiatry: challenges and best practices for studies in children and adolescents. Nemeroff, Suppl 7, 3–4
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. Emslie, Suppl 7, 14–20
Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? [ASCP Corner] Correll, Oct 1331–1332
Prepubertal and early adolescent bipolar I disorder: review of diagnostic validation by Robins and Guze criteria. Geller, Suppl 7, 21–28
Recidivism in medication-noncompliant serious juvenile offenders with bipolar disorder. Dailey, Apr 477–484
Relationship of gender and trauma characteristics to posttraumatic stress disorder in a community sample of traumatized Northern Plains American Indian adolescents and young adults. Gnanadesikan, Sept 1176–1183
Use of antipsychotics in children and adolescents. Findling, Suppl 7, 29–40
Adults
Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. Erhart, Aug 968–973
Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? Hollon, Apr 455–468
Africa
African patient with ziprasidone intolerance [letter]. Hein, June 800
Applying parsimony to "An African Patient With Ziprasidone Intolerance" [letter]. Anders; Hein reply, Nov 1491
Aged in Home Care (AdHOC) Project
Association between pain and depression among older adults in Europe: results from the Aged in Home Care (AdHOC) project: a cross-sectional study. Onder, Aug 982–988
Agitation
Retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. Greco, July 928–929
Alcohol
Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Petry, May 564–574
Dissociative disorders among inpatients with drug or alcohol dependency. Karadag, Oct 1247–1253
Mirtazapine for alcohol dependence: a case report [letter]. Crockford, Apr 540
Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Compton, June 677–685
Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. de Leon, Nov 1447–1455
Algorithms
Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Suppes, July 870–886
Allergic Reactions
Allergic reaction to depot risperidone but not to oral risperidone [letter]. Reeves, July 949
Allopurinol
Clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Brunstein, Feb 213–219
Alzheimer's Disease
Cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. Papassotiropoulos, July 940–947
Focus on Alzheimer's disease and related disorders [editorial]. Reiman, July 816–817
In this issue: genetics, cholesterol, and the risk of Alzheimer's disease. Reiman, July 938–939
Amisulpride
Open-label study of amisulpride in the treatment of mania. Vieta, May 575–578
Anger
Relation between anger expression, depression, and somatic symptoms in depressive disorders and somatoform disorders. Koh, Apr 485–491
Anglo-Americans
Predictors of everyday functioning among older Mexican Americans vs. Anglo-Americans with schizophrenia. Jeste, Oct 1304–1311
Anorexia Nervosa
Use of olanzapine in anorexia nervosa [letter]. Menaster; Barbarich-Marsteller reply, May 655–656
Antidepressants see also specific drugs
Accurate meta-analytical assessment of "true antidepressant effects" needed [letter]. Quitkin; Posternak reply, Sept 1192
Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. Guaiana, June 750–755
Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. Lavretsky, Aug 964–967
Antidepressant treatment outcomes of psychogenic movement disorder. Voon, Dec 1530–1535
Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. Carpenter, Oct 1234–1238
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. Morgan, June 774–780
Is there a delay in the antidepressant effect? a meta-analysis. Posternak, Feb 148–158
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. Emslie, Suppl 7, 14–20
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Thase, Aug 974–981
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. Quitkin, June 670–676
Symptom clusters as predictors of late response to antidepressant treatment. Trivedi, Aug 1064–1070
Underpowered repetitive transcranial magnetic stimulation might not be an effective antidepressant treatment [letter]. Kirov; Koerselman reply, Apr 543–544
Why isn't bupropion the most frequently prescribed antidepressant? Zimmerman, May 603–610
Antihypertensives
Do antihypertensives make tranylcypromine safer? three case reports [letter]. Taylor, May 657–658
Antipsychotics see also specific drugs
Antipsychotic-induced sexual dysfunction and the strength of the evidence [letter]. Rico-Villademoros; Olfson reply, Aug 1074–1076
Antipsychotic medication and diabetes mellitus [letter]. Citrome; Cohen D reply, Mar 395
Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and comorbid psychiatric disorders. Shedlack, Jan 52–62

Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Bowden, Suppl 3, 12–19
Atypical antipsychotics and glucose homeostasis. Bergman, Apr 504–514
Atypical antipsychotics: efficacy across bipolar disorder subpopulations. Dunner, Suppl 3, 20–27
Atypical antipsychotics in bipolar depression: potential mechanisms of action. Yatham, Suppl 5, 40–48
Behavioral treatment of obesity in patients taking antipsychotic medications. Kalarchian, Aug 1058–1063
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Liperoti, Sept 1090–1096
Clinical highlights in bipolar depression: focus on atypical antipsychotics. Calabrese, Suppl 5, 26–33
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: response to consensus statement [letter]. Citrome, Aug 1073–1074
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics [letter]. Karagianis; Alméras reply, Jan 137–138
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. Melkersson, June 761–767
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Tenback, Sept 1130–1133
Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? [ASCP Corner] Nelson, Aug 1071
Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain [letter]. Sharpe; Ganguli reply, July 951–952
Introduction: the role of atypical antipsychotics in the treatment of bipolar disorder. Hirschfeld, Suppl 3, 3–4
Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania? [letter] Treuer; Keck reply, Oct 1333–1334
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. McKee, Sept 1161–1168
Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? [ASCP Corner] Correll, Oct 1331–1332
Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. Marchiaro, Nov 1423–1431
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Aarsland, May 633–637
Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Villeneuve, Oct 1298–1303
Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia [letter]. Tornatore; Kane reply, Nov 1493–1494
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. Blier, Suppl 8, 30–40
Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. McKenna, Apr 444–449
QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. Mackin, Nov 1386–1391
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. de Lima, July 831–838
Real-life dosing with second-generation antipsychotics. Correll, Dec 1611–1612
Role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. Keck, Suppl 3, 5–11
Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Green, Suppl 6, 21–26
Schizophrenia, antipsychotic drugs, and cardiovascular disease. Glassman, Suppl 6, 5–10
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Thyroid dysfunction during treatment with atypical antipsychotics [letter]. Greenspan, Oct 1334–1335
Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. McIntyre, Suppl 3, 28–36
Typical and atypical antipsychotics in bipolar depression. Gao, Nov 1376–1385
Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. Sernyak, Nov 1463–1467
Use of antipsychotics in children and adolescents. Findling, Suppl 7, 29–40
Use of atypical antipsychotics in refractory depression and anxiety. Nemeroff, Suppl 8, 13–21
Weight gain and antipsychotics [letter]. Mackin; Kane reply, July 950–951

Antisocial Personality Syndrome

Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Compton, June 677–685

Antiviral Agents

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Raison, Jan 41–48

Anxiety see also specific disorders

Associations of anxiety-related symptoms with reported history of childhood sexual abuse in schizophrenia spectrum disorders. Lysaker, Oct 1279–1284
Comorbid anxiety and depression. Pollack, Suppl 8, 22–29
Introduction. Nemeroff, Suppl 8, 3–4
Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [letter]. Galynker, Apr 544
Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. Roy-Byrne, Oct 1228–1233
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. Blier, Suppl 8, 30–40
Sequential treatment of mood and anxiety disorders. Fava, Nov 1392–1400
Untangling depression and anxiety: clinical challenges [Academic Highlights]. Nov 1477–1487
Use of atypical antipsychotics in refractory depression and anxiety. Nemeroff, Suppl 8, 13–21
Utilizing Benzodiazepines in Clinical Practice: An Evidence-Based Discussion. Suppl 2, 1–46

Aripiprazole

Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. Simon JS, Oct 1216–1220
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Papakostas, Oct 1326–1330
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Volavka, Nov 1362–1366
Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients [letter]. Cohen, Jan 135–136
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter]. DeQuardo; Lim reply, Mar 396
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Treatment-emergent psychosis with aripiprazole [letter]. Barnas, Oct 1339
Use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. Connor, Jan 49–51

ASCP Corner

Challenges and opportunities in teaching psychopharmacology during residency training. Zisook, July 948
Cultural competence in clinical psychopharmacology. Thompson, June 799
Gender differences in clinical psychopharmacology. Clayton, Sept 1191
Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? Nelson, Aug 1071
Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? Correll, Oct 1331–1332
Reading reports of clinical trial results. Kane, May 653
Real-life dosing with second-generation antipsychotics. Correll, Dec 1611–1612
Sexual function and dysfunction during treatment with psychotropic medications. Balon, Nov 1488–1489

Asperger's Disorder
Open-label risperidone for Asperger's disorder: negative symptom spectrum response. Rausch, Dec 1593–1598
Atomoxetine
Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. Carpenter, Oct 1234–1238
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. Adler, Mar 294–299
Attention-Deficit/Hyperactivity Disorder
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. Wilens, Feb 253–259
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. Adler, Mar 294–299
Augmentation see Drug Therapy, Combination
Autism
Epidemiology of autistic disorder and other pervasive developmental disorders. Fombonne, Suppl 10, 3–8
Neurochemistry in the pathophysiology of autism. McDougle, Suppl 10, 9–18
Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. Findling, Suppl 10, 26–31
Safety issues with drug therapies for autism spectrum disorders. McCracken, Suppl 10, 32–37
Treatment planning for patients with autism spectrum disorders. Aman, Suppl 10, 38–45
Behavior
Behavioral treatment of obesity in patients taking antipsychotic medications. Kalarchian, Aug 1058–1063
Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. Tenneij, Sept 1169–1175
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Brar, Feb 205–212
Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. Findling, Suppl 10, 26–31
Benzodiazepines
Attitudes toward benzodiazepines over the years. Rosenbaum, Suppl 2, 4–8
Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. Stevens, Suppl 2, 21–27
Benzodiazepine use, abuse, and dependence. O'Brien, Suppl 2, 28–33
Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need. Otto, Suppl 2, 34–38
Effects of benzodiazepines on cognition. Stewart, Suppl 2, 9–13
GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. Roy-Byrne, Suppl 2, 14–20
β-Methyl-6-Chloromelatonin
Efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. Zemlan, Mar 384–390
Bipolar Disorder
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Keck, May 611–616
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Bowden, Suppl 3, 12–19
Atypical antipsychotics: efficacy across bipolar disorder subpopulations. Dunner, Suppl 3, 20–27
Atypical antipsychotics in bipolar depression: potential mechanisms of action. Yatham, Suppl 5, 40–48
Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. Garno, Mar 339–345
Burden of Bipolar Illness. Suppl 5, 1–48
Challenges in the management of bipolar depression. Suppes, Suppl 5, 11–16
Cholesterol and lithium levels were correlated but serum HDL and total cholesterol levels were not associated with current mood state in bipolar patients [letter]. Diaz-Sastre, Mar 399–400
Clinical highlights in bipolar depression: focus on atypical antipsychotics. Calabrese, Suppl 5, 26–33
Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. Benedetti, Dec 1536–1541
Complicated grief and its correlates in patients with bipolar disorder. Simon, Sept 1105–1110
Diagnosis and management of patients with bipolar II disorder. Yatham, Suppl 1, 13–17
Does recovery from substance use disorder matter in patients with bipolar disorder? Weiss, June 730–735
Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Weisler, Mar 323–330
Factors associated with medication adherence in African American and white patients with bipolar disorder. Fleck, May 646–652
Focus on bipolar disorder treatment [Academic Highlights]. Dec 1598–1609
Impact of bipolar depression. Post, Suppl 5, 5–10
Improving treatment adherence in bipolar disorder through psychoeducation. Vieta, Suppl 1, 24–29
Introduction: the burden of bipolar depression. Bowden, Suppl 5, 3–4
Introduction: the role of atypical antipsychotics in the treatment of bipolar disorder. Hirschfeld, Suppl 3, 3–4
Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania? [letter] Treuer; Keck reply, Oct 1333–1334
Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. Baethge, Feb 174–182
Long-term treatment in bipolar disorder. Swann, Suppl 1, 7–12
Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Matza, Nov 1432–1440
New Perspectives in Treating Bipolar Disorder. Suppl 1, 1–32
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Osher, June 726–729
Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder [letter]. Chiu, Dec 1613–1614
Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. McElroy, May 617–624
Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. Akiskal, July 914–921
Package of care for patients with bipolar depression. Vieta, Suppl 5, 34–39
Possible bipolar nature of irritability in major depressive disorder [letter]. Benazzi; Perlis reply, Aug 1072–1073
Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. Post, Mar 370–374
Preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. Anand, Feb 195–198
Prepubertal and early adolescent bipolar I disorder: review of diagnostic validation by Robins and Guze criteria. Geller, Suppl 7, 21–28
Prevalence, correlates, and comorbidity of bipolar I disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant BF, Oct 1205–1215
Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Bowden, Jan 111–121
Recidivism in medication-noncompliant serious juvenile offenders with bipolar disorder. Dailey, Apr 477–484
Recognizing and managing bipolar disorder in children. Wozniak, Suppl 1, 18–23
Reevaluating therapies for bipolar depression. Grunze, Suppl 5, 17–25
Retrospective analysis of risk and protective factors for natural death in bipolar disorder. Tsai, Dec 1587–1592
Role of Atypical Antipsychotics in the Treatment of Bipolar Disorder. Suppl 3, 1–50
Role of pharmacologic treatment guidelines for bipolar disorder. Perlis, Suppl 3, 37–47
Role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. Keck, Suppl 3, 5–11
Suicidal ideation and attempts in bipolar I and II disorders. Valtonen, Nov 1456–1462
Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. Hawton, June 693–704

Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Gopal, Aug 1016–1020
Texas implementation of medication algorithms update for treatment of bipolar I disorder [commentary]. Perlis, July 818–820
Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Suppes, July 870–886
Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. McIntyre, Suppl 3, 28–36
Treatment options for bipolar depression. Bowden, Suppl 1, 3–6
Typical and atypical antipsychotics in bipolar depression. Gao, Nov 1376–1385

Blood Pressure

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. Wilens, Feb 253–259

Body Dysmorphic Disorder

Substance use disorders in individuals with body dysmorphic disorder. Grant JE, Mar 309–316
Suicidal ideation and suicide attempts in body dysmorphic disorder. Phillips, June 717–725

Books Reviewed

Ahles SR: *Our Inner World: A Guide to Psychodynamics and Psychotherapy*. Kramer, July 955
Andrews LB, Burruss JW: *Core Competencies for Psychiatric Education: Defining, Teaching, and Assessing Resident Competence*. Rao, July 953–954
Bender S, Messner E: *Becoming a Therapist: What Do I Say, and Why?* Hargrave, Jan 139
Bezchlibnyk-Butler KZ, Virani AS (eds): *Clinical Handbook of Psychotropic Drugs for Children and Adolescents*. van Wattum, Dec 1617
Bowers M Jr: *Abetting Madness: The Role of Illicit and Prescribed Drugs in Promoting Psychotic and Manic Disorders*. Salzman, June 807
Casey BJ (ed): *Developmental Psychobiology*. Petti, Sept 1196
Castle DJ, Murray R (eds): *Marijuana and Madness: Psychiatry and Neurobiology*. Appleton, Aug 1080
Charney DS (ed): *Molecular Neurobiology for the Clinician*. McKinney, Aug 1080–1081
Coombs RH (ed): *Handbook of Addictive Disorders: A Practical Guide to Diagnosis and Treatment*. Ruiz, June 804
Daruna JH: *Introduction to Psychoneuroimmunology*. Salomon, Nov 1496
Dulcan MK, Martini R, Lake MB: *Concise Guide to Child and Adolescent Psychiatry, Third Edition*. Mian, June 806–807
Flem L: *Freud the Man: An Intellectual Biography*. Joseph, May 660–661
Healy D: *The Creation of Psychopharmacology*. Garver, Oct 1340
Lisanby SH (ed): *Brain Stimulation in Psychiatric Treatment*. Black, Nov 1496
Litz BT (ed): *Early Intervention for Trauma and Traumatic Loss*. Findling, Oct 1340
Kadison RD, DiGeronimo TF: *College of the Overwhelmed: The Campus Mental Health Crisis and What to Do About It*. Matthews, Apr 545
Martensen RL: *The Brain Takes Shape: An Early History*. Thienhaus, Aug 1079–1080
Meck WH (ed): *Functional and Neural Mechanisms of Interval Timing*. Salomon, Aug 1078–1079
Neubauer DN: *Understanding Sleeplessness: Perspective on Insomnia*. Rack, June 806
Ozonoff S, Rogers SJ, Hendren RL (eds): *Autism Spectrum Disorders: A Research Review for Practitioners*. Tanguay, Feb 271–272
Peteet JR: *Doing the Right Thing: An Approach to Moral Issues in Mental Health Treatment*. Wells, Aug 1079
Petit JR: *Handbook of Emergency Psychiatry*. Miller MC, Mar 402–403
Roose SP, Sackeim HA (eds): *Late-Life Depression*. Brown, Apr 545
Roukema RW: *What Every Patient, Family, Friend, and Caregiver Needs to Know About Psychiatry, 2nd ed*. Burkholder, Jan 139
Sadock BJ, Sadock VA, Jones RM: *Kaplan and Sadock's Study Guide and Self-Examination Review in Psychiatry, Seventh Edition*. Bernstein, Mar 402
Salzman C (ed): *Clinical Geriatric Psychopharmacology, 4th ed*. Ellison, June 805–806
Simon RI: *Assessing and Managing Suicide Risk: Guidelines for Clinically Based Risk Management*. Hirschowitz, June 804–805
Stein DJ (ed): *The Clinical Manual of Anxiety Disorders*. Goldberg, Feb 271
Tasman A, Kay J, Lieberman JA (eds): *Psychiatry, vols 1 and 2, 2nd ed*. Wells, July 954–955
Trimble M: *Somatoform Disorders: A Medicolegal Guide*. Streltzer, Aug 1081
Ursano RJ, Norwood AE (eds): *Trauma & Disaster: Responses & Management*. Risby, Mar 402
Ursano RJ, Sonnenberg SM, Lazar SG: *Concise Guide to Psychodynamic Psychotherapy: Principles and Techniques of Brief, Intermittent, and Long-Term Psychodynamic Psychotherapy, 3rd ed*. Lomax, Aug 1078
van Praag HM, de Kloet R, van Os J: *Stress, the Brain and Depression*. Salzman, July 954
Wyszynski AA, Wyszynski B (eds): *Manual of Psychiatric Care for the Medically Ill*. Chiles, Dec 1618
Yudofsky SC, Kim HF (eds): *Neuropsychiatric Assessment*. Kirshner, Dec 1617–1618

Borderline Personality Disorder

Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder [letter]. Pittenger, Nov 1492–1493
Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Villeneuve, Oct 1298–1303
Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. Bellino, Sept 1111–1115

Botulinum Toxin

Case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A [letter]. Chen, Feb 267–268

Bradyphylaxis

It looks like "bradyphylaxis" to me [letter]. Jefferson; Solomon DA reply. Aug 1076–1077

Brain

Abnormal regional cerebral blood flow in systemic lupus erythematosus patients with psychiatric symptoms. Oda, July 907–913
Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. Lavretsky, Aug 964–967

Brainstorms

Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder? Stahl, Jan 5–6

Bromocriptine

Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report [letter]. Miller, Feb 269–270

Bupropion

Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. Vulink, Feb 228–230
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Evins, Sept 1184–1190
Placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. DeBattista, July 844–848
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Thase, Aug 974–981
Weight gain, sexual dysfunction, and bupropion [letter]. Menaster; Zimmerman reply, Oct 1335–1339
Why isn't bupropion the most frequently prescribed antidepressant? Zimmerman, May 603–610

Carbamazepine

Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Weisler, Mar 323–330
Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. Baethge, Feb 174–182
Serious rash with lamotrigine after carbamazepine discontinuation: a case report [letter]. Subuh Surja, Mar 400–401

Cardiovascular Health

Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Henderson, Sept 1116–1121
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. O'Connor, Mar 346–352
Schizophrenia, antipsychotic drugs, and cardiovascular disease. Glassman, Suppl 6, 5–10

Carnitine
Carnitine levels in valproic acid–treated psychiatric patients: a cross-sectional study. Moreno, May 555–558
Catatonia
Catatonia is a risk factor for neuroleptic malignant syndrome [letter]. Carroll, 2004 Dec 1722–1723; Ananth reply, Jan 134
Cerebrovascular Health
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Liperoti, Sept 1090–1096
Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? [ASCP Corner] Nelson, Aug 1071
Children
Associations of anxiety-related symptoms with reported history of childhood sexual abuse in schizophrenia spectrum disorders. Lysaker, Oct 1279–1284
Clinical differences between suicidal and nonsuicidal depressed children and adolescents. Barbe, Apr 492–498
Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child [letter]. Mendhekar, Dec 1616
Introduction. Developmental neurobiology and psychiatry: challenges and best practices for studies in children and adolescents. Nemeroff, Suppl 7, 3–4
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. Emslie, Suppl 7, 14–20
Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? [ASCP Corner] Correll, Oct 1331–1332
Prepubertal and early adolescent bipolar I disorder: review of diagnostic validation by Robins and Guze criteria. Geller, Suppl 7, 21–28
Recognizing and managing bipolar disorder in children. Wozniak, Suppl 1, 18–23
Use of antipsychotics in children and adolescents. Findling, Suppl 7, 29–40
Chinese
Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. Su, July 930–937
Chinese Medicine
Effects of the traditional Chinese herbal medicine *Yi-Gan San* for cholinesterase inhibitor–resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies [letter]. Iwasaki, Dec 1612–1613
Randomized, observer-blind, controlled trial of the traditional Chinese medicine *Yi-Gan San* for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. Iwasaki, Feb 248–252
Cholesterol
Cholesterol and lithium levels were correlated but serum HDL and total cholesterol levels were not associated with current mood state in bipolar patients [letter]. Diaz-Sastre, Mar 399–400
Cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. Papassotiropoulos, July 940–947
In this issue: genetics, cholesterol, and the risk of Alzheimer's disease. Reiman, July 938–939
Chronic Fatigue
Prospective observational study of treatments for unexplained chronic fatigue. Bentler, May 625–632
Circadian System
Human circadian system in normal and disordered sleep. Richardson, Suppl 9, 3–9
Citalopram
Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. Rocca, Mar 360–369
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Landén, Jan 100–106
Clinical Trials
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. Emslie, Suppl 7, 14–20
Reading reports of clinical trial results [ASCP Corner]. Kane, May 653
Clonidine
Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child [letter]. Mendhekar, Dec 1616
Clozapine
Addition of lamotrigine to clozapine in inpatients with chronic psychosis [letter]. Heck, Oct 1333
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Henderson, Sept 1116–1121
Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. Modestin, Apr 534–538
Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash [letter]. Bhatti, Nov 1490–1491
Commentary: suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Meltzer, Apr 530–533
Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. Lamberti, July 900–906
Double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Yağcıoğlu, Jan 63–72
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter]. DeQuardo; Lim reply, Mar 396
Cognition
Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need. Otto, Suppl 2, 34–38
Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. Otto, Suppl 4, 28–32
Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. van Oppen, Nov 1415–1422
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Sevy, July 839–843
Effects of benzodiazepines on cognition. Stewart, Suppl 2, 9–13
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Evins, Sept 1184–1190
Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety [letter]. McClendon; Misri reply, Nov 1494–1495
Schizophrenia patients with a history of severe violence differ from nonviolent schizophrenia patients in perception of emotions but not cognitive function. Silver, Mar 300–308
Comorbidity
Abnormal regional cerebral blood flow in systemic lupus erythematosus patients with psychiatric symptoms. Oda, July 907–913
Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. Garno, Mar 339–345
Clinical characteristics and psychiatric comorbidity in males with exhibitionism. Grant JE, Nov 1367–1371
Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Petry, May 564–574
Implications of medical and psychiatric comorbidity with panic disorder. Simon, Suppl 4, 8–15
Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Matza, Nov 1432–1440
Neurologic comorbidities in schizophrenia. Nasrallah, Suppl 6, 34–46
New Therapies for Treatment-Resistant Depression and Anxiety. Suppl 8, 1–43
Overview of common medical comorbidities in patients with schizophrenia. Nasrallah, Suppl 6, 3–4
Prevalence, correlates, and comorbidity of bipolar I disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant BF, Oct 1205–1215
Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Compton, June 677–685
Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. Cournos, Suppl 6, 27–33
Schizophrenia and comorbid metabolic disorders. Henderson, Suppl 6, 11–20
Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Green, Suppl 6, 21–26
Schizophrenia, antipsychotic drugs, and cardiovascular disease. Glassman, Suppl 6, 5–10
Compliance see Medication Adherence
Conduct Disorder
Baseline predictors of response to divalproex in conduct disorder. Saxena, Dec 1542–1549
Corrections
Case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics [letter]. 2004 Nov 1576–1577. Correction, Jan 138

Extended-release carbamazepine capsules as a monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Weisler, Mar 323–330. Correction, May 659
Prophylactic antipsychotics: do they keep you from catching schizophrenia? Stahl, 2004 Nov 1445–1446. Correction, Mar 401
Topiramate in the long-term treatment of binge-eating disorder associated with obesity. McElroy, 2004 Nov 1463–1469. Correction, Jan 138

Costs of Medical Care

Economic burden of schizophrenia in the United States in 2002. Wu, Sept 1122–1129
Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Matza, Nov 1432–1440
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. O'Connor, Mar 346–352

Culture

Cultural competence in clinical psychopharmacology [ASCP Corner]. Thompson, June 799

Cyclobenzaprine

Interactions of cyclobenzaprine and tricyclic antidepressants [letter]. Rosenlicht, Jan 134–135

Cytochrome P450

CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. de Leon, Jan 15–27

Delirium

Case of delirium and subsequent pancytopenia associated with the oral loading of valproic acid [letter]. Chae, June 801–802
Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. Shulman, Apr 424–427

Dementia

Effects of the traditional Chinese herbal medicine *Yi-Gan San* for cholinesterase inhibitor–resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies [letter]. Iwasaki, Dec 1612–1613
Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? [ASCP Corner] Nelson, Aug 1071
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Aarsland, May 633–637
Randomized, observer-blind, controlled trial of the traditional Chinese medicine *Yi-Gan San* for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. Iwasaki, Feb 248–252

Demographics

Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Novick, Aug 1002–1011

Depression

Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. Su, July 930–937
Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. Lavretsky, Aug 964–967
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. Simon JS, Oct 1216–1220
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Papakostas, Oct 1326–1330
Assessing demoralization and depression in the setting of medical disease. Mangelli, Mar 391–394
Association between pain and depression among older adults in Europe: results from the Aged in Home Care (AdHOC) project: a cross-sectional study. Onder, Aug 982–988
Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. Rocca, Mar 360–369
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Novick, Aug 1002–1011
Clinical differences between suicidal and nonsuicidal depressed children and adolescents. Barbe, Apr 492–498
Clinical predictors of suicide in primary major depressive disorder. Coryell, Apr 412–417
Comorbid anxiety and depression. Pollack, Suppl 8, 22–29
Continuity is the main challenge in treating major depressive disorder in psychiatric care. Melartin, Feb 220–227
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. Nemets, May 586–590
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Raison, Jan 41–48
Differences between minimally depressed patients who do and do not consider themselves to be in remission. Zimmerman, Sept 1134–1138
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial. Rossini, Dec 1570–1576
Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Murray, June 708–716
8-Week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. Simpson, May 598–602
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. Morgan, June 774–780
Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. Hornyak, Sept 1139–1145
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Landén, Jan 100–106
Introduction. Nemeroff, Suppl 8, 3–4
Issues in treatment-resistant depression. Keller, Suppl 8, 5–12
Long-term maintenance therapy for major depressive disorder with rTMS. O'Reardon, Dec 1525–1529
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Andersen, Nov 1468–1476
Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [letter]. Galynker, Apr 544
Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. Shores, Jan 7–14
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. Emslie, Suppl 7, 14–20
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Constant, Aug 1050–1057
Neurobiology of depression: inroads to treatment and new drug discovery. Nemeroff, Suppl 7, 5–13
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Shelton, Oct 1289–1297
Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. Sharpley, Apr 450–454
Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Osher, June 726–729
Open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Iosifescu, Aug 1038–1042
Pain predicts longer time to remission during treatment of recurrent depression. Karp, May 591–597
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. O'Connor, Mar 346–352
Placebo response in psychotic depression [letter]. Rothschild; Simpson reply, Dec 1615–1616
Possible bipolar nature of irritability in major depressive disorder [letter]. Benazzi; Perlis reply, Aug 1072–1073
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. Blier, Suppl 8, 30–40
Predictors of remission after electroconvulsive therapy in unipolar major depression. Dombrovski, Aug 1043–1049
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Perlis, Feb 159–166
Prevalence of maternal depressive symptoms in low-income Hispanic women. Chaudron, Apr 418–423
Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? Hollon, Apr 455–468
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Sir, Oct 1312–1320

Relation between anger expression, depression, and somatic symptoms in depressive disorders and somatoform disorders. Koh, Apr 485–491
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. Quitkin, June 670–676
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. Nelson, Nov 1409–1414
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. Deigado, June 686–692
Sleep and depression. Tsuno, Oct 1254–1269
Tachyphylaxis in unipolar major depressive disorder. Solomon, Mar 283–290
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. Nahas, Sept 1097–1104
Untangling depression and anxiety: clinical challenges [ACADEMIC HIGHLIGHTS]. Nov 1477–1487
Use of atypical antipsychotics in refractory depression and anxiety. Nemeroff, Suppl 8, 13–21
Weight changes in postpartum women with remitted depression. Gracious, Mar 291–293

Dermatitis
Differential modulation of cerebrospinal fluid neurotrophins in patients with atopic dermatitis who attempted suicide [letter]. Kimata, Sept 1193–1194

Dermatology
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. Ketter, May 642–645

Developmental Disabilities
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. McKee, Sept 1161–1168

Diabetes
Antipsychotic medication and diabetes mellitus [letter]. Citrome; Cohen D reply, Mar 395
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Henderson, Sept 1116–1121
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: response to consensus statement [letter]. Citrome, Aug 1073–1074
Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. Lamberti, July 900–906
Diabetes mellitus during olanzapine and quetiapine treatment in Japan [letter]. Cohen D; Misawa reply, Feb 265–267
New onset of diabetes mellitus with ziprasidone: a case report [letter]. Sánchez-Barranco, Feb 268–269
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173

Diagnosis
Diagnosis and evaluation of pervasive developmental disorders. Scahill, Suppl 10, 19–25
Diagnostic stability 18 months after treatment initiation for first-episode psychosis. Schimmelmann, Oct 1239–1246
Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. Akiskal, July 914–921

Disclosure
Funding, conflicts, and paradigms [editorial]. Gelenberg, May 554

Discontinuation
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Sir, Oct 1312–1320

Dissociative Disorders
Dissociative disorders among inpatients with drug or alcohol dependency. Karadag, Oct 1247–1253

Divalproex
Baseline predictors of response to divalproex in conduct disorder. Saxena, Dec 1542–1549

Donepezil
Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. Bergman, Jan 107–110

Dosage
Lithium dosing schedule and renal insufficiency [letter]. Smith; Lepkifker reply, Mar 396–397
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases. Kim, July 887–893
Single versus multiple daily dosing of lithium: renal effects [letter]. Shammi; Lepkifker reply, Mar 398–399

Driving
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. Wingen, Apr 436–443

Drug Administration
Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. Tenneij, Sept 1169–1175

Drug Safety
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Davidson, Nov 1441–1446

Drug Therapy, Combination
Addition of lamotrigine to clozapine in inpatients with chronic psychosis [letter]. Heck, Oct 1333
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. Simon JS, Oct 1216–1220
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Papakostas, Oct 1326–1330
Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. Carpenter, Oct 1234–1238
Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. van Oppen, Nov 1415–1422
Double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Yağcıoğlu, Jan 63–72
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. Morgan, June 774–780
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter]. DeQuardo; Lim reply, Mar 396
Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. Baethge, Feb 174–182
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Andersen, Nov 1468–1476
Multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Fava, Jan 85–93
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Shelton, Oct 1289–1297
Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. McElroy, May 617–624
Open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Iosifescu, Aug 1038–1042
Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. Roy-Byrne, Oct 1228–1233
Placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. DeBattista, July 844–848
Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. Post, Mar 370–374
Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? Hollon, Apr 455–468
Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. Bogan, Jan 73–79
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li, June 736–743
Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Tiihonen, Aug 1012–1015

Dual Reuptake Inhibitors
Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. Posternak, June 705–707

Duloxetine
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. Delgado, June 686–692

Elderly
Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. Lavretsky, Aug 964–967

Association between pain and depression among older adults in Europe: results from the Aged in Home Care (AdHOC) project: a cross-sectional study. Onder, Aug 982–988
Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. Bergman, Jan 107–110
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Liperoti, Sept 1090–1096
Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. Rocca, Mar 360–369
Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. Shulman, Apr 424–427
Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? [ASCP Corner] Nelson, Aug 1071
Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. Shores, Jan 7–14
Predictors of everyday functioning among older Mexican Americans vs. Anglo-Americans with schizophrenia. Jeste, Oct 1304–1311
Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? Hollon, Apr 455–468
Retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. Greco, July 928–929
Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. Ancoli-Israel, Suppl 9, 24–30

Electroconvulsive Therapy
Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder [letter]. Chaves, Apr 542–543
Predictors for the efficacy of electroconvulsive therapy: chart review of a naturalistic study. Kho, July 894–899
Predictors of remission after electroconvulsive therapy in unipolar major depression. Dombrovski, Aug 1043–1049

England
Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. Abel, June 781–789

Epidemiology
Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Petry, May 564–574
Epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant BF, Nov 1351–1361

Escitalopram
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. Wingen, Apr 436–443
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial. Rossini, Dec 1570–1576
Preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. Freeman EW, June 769–773
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Davidson, Nov 1441–1446
24-Week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Montgomery, Oct 1270–1278

Estrogen
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. Morgan, June 774–780

Ethnicity
Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. Roy-Byrne, Oct 1228–1233

Europe
Association between pain and depression among older adults in Europe: results from the Aged in Home Care (AdHOC) project: a cross-sectional study. Onder, Aug 982–988

European Schizophrenia Outpatient Health Outcomes (SOHO) Study
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Tenback, Sept 1130–1133

Evidence-Based Medicine
Commentary: suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Meltzer, Apr 530–533

Exhibitionism
Clinical characteristics and psychiatric comorbidity in males with exhibitionism. Grant JE, Nov 1367–1371

Fatigue
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Sevy, July 839–843

Finland
4-Fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. Saari, May 559–563
Recovery from schizophrenic psychoses within the Northern Finland 1966 Birth Cohort. Lauronen, Mar 375–383

Fluoxetine
Case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A [letter]. Chen, Feb 267–268
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. Nemets, May 586–590
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Andersen, Nov 1468–1476
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. Nelson, Nov 1409–1414

Fluphenazine
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Kelly, Jan 80–84

Fluvoxamine
Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. van Oppen, Nov 1415–1422

Galactorrhea
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report [letter]. Miller, Feb 269–270

Gender
Gender differences in clinical psychopharmacology [ASCP Corner]. Clayton, Sept 1191
Relationship of gender and trauma characteristics to posttraumatic stress disorder in a community sample of traumatized Northern Plains American Indian adolescents and young adults. Gnanadesikan, Sept 1176–1183

Generalized Anxiety Disorder
Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Brawman-Mintzer, Oct 1321–1325
Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [letter]. Schutters, Apr 540–542
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Davidson, Nov 1441–1446
Selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. Pollack, Nov 1401–1408
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Ball, Jan 94–99

Genetics
Cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. Papassotiropoulos, July 940–947
CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. de Leon, Jan 15–27
Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. Lochner, Sept 1155–1160
In this issue: genetics, cholesterol, and the risk of Alzheimer's disease. Reiman, July 938–939
Psychiatric genetics: a survey of psychiatrists' knowledge, opinions, and practice patterns. Finn, July 821–830

Geriatric Psychiatry see Elderly

Glucose
Atypical antipsychotics and glucose homeostasis. Bergman, Apr 504–514

Glutamate-Modulating Agents
Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder [letter]. Pittenger, Nov 1492–1493

Grief
Complicated grief and its correlates in patients with bipolar disorder. Simon, Sept 1105–1110

Guidelines
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. Goff, Feb 183–194
Role of pharmacologic treatment guidelines for bipolar disorder. Perlis, Suppl 3, 37–47
Gynecomastia
Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child [letter]. Mendhekar, Dec 1616
Hallucinations
Effects of the traditional Chinese herbal medicine *Yi-Gan San* for cholinesterase inhibitor–resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies [letter]. Iwasaki, Dec 1612–1613
Haloperidol
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick, May 638–641
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach, Aug 1021–1030
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li, June 736–743
Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Diav-Citrin, Mar 317–322
Hepatitis
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Raison, Jan 41–48
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Constant, Aug 1050–1057
Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. Cournos, Suppl 6, 27–33
Hispanics
Prevalence of maternal depressive symptoms in low-income Hispanic women. Chaudron, Apr 418–423
Hoarding
Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. Lochner, Sept 1155–1160
Homocysteine
High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. Lerner, Dec 1559–1564
Hostility
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Volavka, Nov 1362–1366
Human Immunodeficiency Virus
Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. Cournos, Suppl 6, 27–33
Hurricane Katrina
Hurricane Katrina: a physician's whirlwind course in disaster psychiatry [commentary]. Spicer, Nov 1349–1350
Hyperglycemia
Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. Sernyak, Nov 1463–1467
Hyperlipidemia
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Henderson, Sept 1116–1121
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Hyperprolactinemia
Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child [letter]. Mendhekar, Dec 1616
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report [letter]. Miller, Feb 269–270
Hypertension
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Hypnotic Drugs
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. Griffiths, Suppl 9, 31–41
Hypochondriasis
Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine [letter]. Chand, June 800–801
Hypomania
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Constant, Aug 1050–1057
Hypotension
Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam [letter]. Zacher, Dec 1614–1615
Impulsivity
Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Villeneuve, Oct 1298–1303
Infants
Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. Abel, June 781–789
Inpatients
Addition of lamotrigine to clozapine in inpatients with chronic psychosis [letter]. Heck, Oct 1333
Dissociative disorders among inpatients with drug or alcohol dependency. Karadag, Oct 1247–1253
Insomnia
Efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. Zemlan, Mar 384–390
Human circadian system in normal and disordered sleep. Richardson, Suppl 9, 3–9
Insomnia: a primary care perspective. Culpepper, Suppl 9, 14–17
Prevalence, associated risks, and treatment patterns of insomnia. Roth, Suppl 9, 10–13
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. Griffiths, Suppl 9, 31–41
Review of the evidence for the efficacy and safety of trazodone in insomnia. Mendelson, Apr 469–476
Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. Ancoli-Israel, Suppl 9, 24–30
Therapeutic options in the treatment of insomnia. Erman, Suppl 9, 18–23
Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach, Aug 1021–1030
Interferon Alpha Therapy
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Raison, Jan 41–48
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Constant, Aug 1050–1057
Intermittent Explosive Disorder
Prevalence and features of intermittent explosive disorder in a clinical setting. Coccaro, Oct 1221–1227
Irritability
Possible bipolar nature of irritability in major depressive disorder [letter]. Benazzi; Perlis reply, Aug 1072–1073
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Perlis, Feb 159–166
Israel
Posttraumatic stress disorder among Israeli ex–prisoners of war 18 and 30 years after release. Solomon Z, Aug 1031–1037
Stress-related responses after 3 years of exposure to terror in Israel: are ideological-religious factors associated with resilience? Kaplan, Sept 1146–1154
Italy
Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. Guaiana, June 750–755
Japan
Diabetes mellitus during olanzapine and quetiapine treatment in Japan [letter]. Cohen D; Misawa reply, Feb 265–267
Journal of Clinical Psychiatry
Another year passes [editorial]. Gelenberg, Dec 1508–1512
Enriching our heritage [publisher note]. Mar 281–282
Focus on Alzheimer's disease and related disorders [editorial]. Reiman, July 816–817
Funding, conflicts, and paradigms [editorial]. Gelenberg, May 554
2005—a year of accomplishments [publisher note]. Dec 1506

Lamotrigine
Addition of lamotrigine to clozapine in inpatients with chronic psychosis [letter]. Heck, Oct 1333
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. Ketter, May 642–645
Serious rash with lamotrigine after carbamazepine discontinuation: a case report [letter]. Subuh Surja, Mar 400–401
Levetiracetam
Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. Post, Mar 370–374
Light Therapy
Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. Benedetti, Dec 1536–1541
Lithium
Cholesterol and lithium levels were correlated but serum HDL and total cholesterol levels were not associated with current mood state in bipolar patients [letter]. Diaz-Sastre, Mar 399–400
Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. Shulman, Apr 424–427
Lithium dosing schedule and renal insufficiency [letter]. Smith; Lepkifker reply, Mar 396–397
Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. Baethge, Feb 174–182
Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Bowden, Jan 111–121
Single versus multiple daily dosing of lithium: renal effects [letter]. Shammi; Lepkifker reply, Mar 398–399
Lorazepam
Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam [letter]. Zacher, Dec 1614–1615
Lupus
Abnormal regional cerebral blood flow in systemic lupus erythematosus patients with psychiatric symptoms. Oda, July 907–913
Magnetic Resonance Imaging
Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. Erhart, Aug 968–973
Mania
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Keck, May 611–616
Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Weisler, Mar 323–330
Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania? [letter] Treuer; Keck reply, Oct 1333–1334
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Constant, Aug 1050–1057
Open-label study of amisulpride in the treatment of mania. Vieta, May 575–578
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Gopal, Aug 1016–1020
Medical Education
Challenges and opportunities in teaching psychopharmacology during residency training [ASCP Corner]. Zisook, July 948
Medical Illness
Assessing demoralization and depression in the setting of medical disease. Mangelli, Mar 391–394
Overview of common medical comorbidities in patients with schizophrenia. Nasrallah, Suppl 6, 3–4
Medication Adherence
Factors associated with medication adherence in African American and white patients with bipolar disorder. Fleck, May 646–652
Improving treatment adherence in bipolar disorder through psychoeducation. Vieta, Suppl 1, 24–29
Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia [letter]. Tornatore; Kane reply, Nov 1493–1494
Trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. Byerly, Aug 997–1001
Mefloquine
Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. van Riemsdijk, Feb 199–204
Melatonin
Efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. Zemlan, Mar 384–390
Memantine
Development of subtle psychotic symptoms with memantine: a case report [letter]. Huey, May 658–659
Men
Clinical characteristics and psychiatric comorbidity in males with exhibitionism. Grant JE, Nov 1367–1371
High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. Lerner, Dec 1559–1564
Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. Shores, Jan 7–14
Male sexual dysfunction and quality of life in schizophrenia. Olfson, Mar 331–338
Mental Illness
Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues [Academic Highlights]. June 790–798
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Wellness intervention for patients with serious and persistent mental illness. Hoffmann, Dec 1577–1580
Mental Retardation
Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and comorbid psychiatric disorders. Shedlack, Jan 52–62
Meta-Analysis
Accurate meta-analytical assessment of "true antidepressant effects" needed [letter]. Quitkin; Posternak reply, Sept 1192
Is there a delay in the antidepressant effect? a meta-analysis. Posternak, Feb 148–158
Metabolism
Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues [Academic Highlights]. June 790–798
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics [letter]. Karagianis; Alméras reply, Jan 137–138
4-Fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. Saari, May 559–563
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. McKee, Sept 1161–1168
Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? [ASCP Corner] Correll, Oct 1331–1332
QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. Mackin, Nov 1386–1391
Schizophrenia and comorbid metabolic disorders. Henderson, Suppl 6, 11–20
Mexican Americans
Predictors of everyday functioning among older Mexican Americans vs. Anglo-Americans with schizophrenia. Jeste, Oct 1304–1311
Mifepristone
8-Week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. Simpson, May 598–602
Mirtazapine
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. Wingen, Apr 436–443
Mirtazapine for alcohol dependence: a case report [letter]. Crockford, Apr 540
Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Koran, Apr 515–520
Modafinil
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Sevy, July 839–843
Multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Fava, Jan 85–93
Mood
Cholesterol and lithium levels were correlated but serum HDL and total cholesterol levels were not associated with current mood state in bipolar patients [letter]. Diaz-Sastre, Mar 399–400

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Constant, Aug 1050–1057
Obesity and mood disorders: the complex problem of insight [letter]. Ravaldi, Feb 265
Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. Roy-Byrne, Oct 1228–1233
Sequential treatment of mood and anxiety disorders. Fava, Nov 1392–1400
Mood Stabilizers
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Bowden, Suppl 3, 12–19
Morphine
Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. Koran, Mar 353–357
Movement Disorders
Antidepressant treatment outcomes of psychogenic movement disorder. Voon, Dec 1530–1535
Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. Bergman, Jan 107–110
Case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A [letter]. Chen, Feb 267–268
Musical Hallucinations
Problems in assessing musical hallucinations [letter]. Teunisse; Hermesh reply, Jan 136–137
Myocardial Infarction
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. O'Connor, Mar 346–352
National Epidemiologic Survey on Alcohol and Related Conditions
Epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant BF, Nov 1351–1361
Prevalence, correlates, and comorbidity of bipolar I disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant BF, Oct 1205–1215
Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Compton, June 677–685
Native Americans
Relationship of gender and trauma characteristics to posttraumatic stress disorder in a community sample of traumatized Northern Plains American Indian adolescents and young adults. Gnanadesikan, Sept 1176–1183
Netherlands
Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. van Riemsdijk, Feb 199–204
Neurobiology
Developmental Neurobiology and Psychiatry: Challenges and Best Practices for Studies in Children and Adolescents. Suppl 7, 1–40
Introduction. Developmental neurobiology and psychiatry: challenges and best practices for studies in children and adolescents. Nemeroff, Suppl 7, 3–4
Neurobiology and etiology of panic disorder. Ninan, Suppl 4, 3–7
Neurobiology of depression: inroads to treatment and new drug discovery. Nemeroff, Suppl 7, 5–13
Neuroleptic Malignant Syndrome
Catatonia is a risk factor for neuroleptic malignant syndrome [letter]. Carroll, 2004 Dec 1722–1723; Ananth reply, Jan 134
Neurotransmitters
GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. Roy-Byrne, Suppl 2, 14–20
Neurotrophins
Differential modulation of cerebrospinal fluid neurotrophins in patients with atopic dermatitis who attempted suicide [letter]. Kimata, Sept 1193–1194
Noncompliance
Recidivism in medication-noncompliant serious juvenile offenders with bipolar disorder. Dailey, Apr 477–484
Nortriptyline
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Shelton, Oct 1289–1297
Obesity see Weight
Obsessive-Compulsive Disorder
Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. Tenneij, Sept 1169–1175
Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. Vulink, Feb 228–230
Clinical predictors of drug nonresponse in obsessive-compulsive disorder. Shetti, Dec 1518–1524
Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. van Oppen, Nov 1415–1422
Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. Tolin, Dec 1550–1558
Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. Koran, Mar 353–357
Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder [letter]. Chaves, Apr 542–543
11- to 13-year follow-up of 75 subjects with obsessive-compulsive disorder. Reddy, June 744–749
Female reproductive cycle and obsessive-compulsive disorder. Labad, Apr 428–435
Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. Lochner, Sept 1155–1160
Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Koran, Apr 515–520
Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. Bogan, Jan 73–79
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li, June 736–743
Severe obsessive-compulsive disorder with and without comorbid hair pulling: comparisons and clinical implications. Stewart SE, July 864–869
Use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. Connor, Jan 49–51
Olanzapine
Diabetes mellitus during olanzapine and quetiapine treatment in Japan [letter]. Cohen D; Misawa reply, Feb 265–267
Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam [letter]. Zacher, Dec 1614–1615
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Andersen, Nov 1468–1476
Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine [letter]. Chand, June 800–801
Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. Sharpley, Apr 450–454
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report [letter]. Miller, Feb 269–270
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Kraus, Dec 1565–1569
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. de Lima, July 831–838
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach, Aug 1021–1030
Use of olanzapine in anorexia nervosa [letter]. Menaster; Barbarich-Marsteller reply, May 655–656
Olanzapine/Fluoxetine Combination
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Keck, May 611–616
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Shelton, Oct 1289–1297
Omega-3 Eicosapentaenoic Acid
Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Osher, June 726–729
Omega-3 Fatty Acids
Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder [letter]. Chiu, Dec 1613–1614

Ondansetron
Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. Toren, Apr 499–503
Opioids
Reduction of opioid-withdrawal symptoms with quetiapine. Pinkofsky, Oct 1285–1288
Organic Syndromes
Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. Erhart, Aug 968–973
Outpatients
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Novick, Aug 1002–1011
Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. Lamberti, July 900–906
Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. Akiskal, July 914–921
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. Quitkin, June, 670–676
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. Byerly, Aug 997–1001
Oxcarbazepine
Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. Bellino, Sept 1111–1115
Pain
Association between pain and depression among older adults in Europe: results from the Aged in Home Care (AdHOC) project: a cross-sectional study. Onder, Aug 982–988
Injection site pain with long-acting risperidone [letter]. Pinninti; Lindenmayer reply, May 656–657
Pain predicts longer time to remission during treatment of recurrent depression. Karp, May 591–597
Pancytopenia
Case of delirium and subsequent pancytopenia associated with the oral loading of valproic acid [letter]. Chae, June 801–802
Panic Disorder
Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. Otto, Suppl 4, 28–32
Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Sheehan, Jan 34–40
Implications of medical and psychiatric comorbidity with panic disorder. Simon, Suppl 4, 8–15
Neurobiology and etiology of panic disorder. Ninan, Suppl 4, 3–7
New Insights Into the Nature and Treatment of Panic Disorder. Suppl 4, 1–36
Pharmacotherapy of panic disorder. Pollack, Suppl 4, 23–27
Understanding and treating panic disorder in the primary care setting. Roy-Byrne, Suppl 4, 16–22
Paraphilias
Issues to consider in the assessment and treatment of paraphilic patients [letter]. Saleh; Briken reply, June 802–803
Parenting
Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. Abel, June 781–789
Parkinson's Disease
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Aarsland, May 633–637
Paroxetine
Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Sheehan, Jan 34–40
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Landén, Jan 100–106
Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. Roy-Byrne, Oct 1228–1233
Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety [letter]. McClendon; Misri reply, Nov 1494–1495
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Ball, Jan 94–99
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. Delgado, June 686–692
Pathological Gambling
Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Petry, May 564–574
Sertraline treatment of pathological gambling: a pilot study. Saiz-Ruiz, Jan 28–33
Penfluridol
Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Diav-Citrin, Mar 317–322
Perimenopause
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. Morgan, June 774–780
Personality Disorder
Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. Garno, Mar 339–345
Pervasive Developmental Disorders
Diagnosis and evaluation of pervasive developmental disorders. Scahill, Suppl 10, 19–25
Epidemiology of autistic disorder and other pervasive developmental disorders. Fombonne, Suppl 10, 3–8
Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. Findling, Suppl 10, 26–31
The Management of Autism and Its Related Disorders. Suppl 10, 1–48
Pharmacoeconomics see Costs of Medical Care
Phenotype
CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. de Leon, Jan 15–27
Phenytoin
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. Nemets, May 586–590
Pheochromocytoma
Relapsing paranoid psychosis as the first manifestation of pheochromocytoma [letter]. Benabarre, July 949–950
Physical Symptoms
Relation between anger expression, depression, and somatic symptoms in depressive disorders and somatoform disorders. Koh, Apr 485–491
Polydipsia-Hyponatremia Syndrome
Treatment of the polydipsia-hyponatremia syndrome with urea. Verhoeven, Nov 1372–1375
Polyserositis
Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash [letter]. Bhatti, Nov 1490–1491
Posttraumatic Stress Disorder
Dissociation and posttraumatic stress 1 year after the World Trade Center disaster: follow-up of a longitudinal survey. Simeon, Feb 231–237
Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder? [BRAINSTORMS] Stahl, Jan 5–6
Posttraumatic stress disorder among Israeli ex–prisoners of war 18 and 30 years after release. Solomon Z, Aug 1031–1037
Relationship of gender and trauma characteristics to posttraumatic stress disorder in a community sample of traumatized Northern Plains American Indian adolescents and young adults. Gnanadesikan, Sept 1176–1183
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. Kozarić-Kovačić, July 922–927
Stress-related responses after 3 years of exposure to terror in Israel: are ideological-religious factors associated with resilience? Kaplan, Sept 1146–1154
Prediction
Baseline predictors of response to divalproex in conduct disorder. Saxena, Dec 1542–1549
Clinical predictors of drug nonresponse in obsessive-compulsive disorder. Shetti, Dec 1518–1524
Clinical predictors of suicide in primary major depressive disorder. Coryell, Apr 412–417
Predictors for the efficacy of electroconvulsive therapy: chart review of a naturalistic study. Kho, July 894–899
Predictors of remission after electroconvulsive therapy in unipolar major depression. Dombrovski, Aug 1043–1049
Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. Abel, June 781–789
Symptom clusters as predictors of late response to antidepressant treatment. Trivedi, Aug 1064–1070

Pregnancy
Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. McKenna, Apr 444–449
Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Diav-Citrin, Mar 317–322
Premenstrual Dysphoric Disorder
Preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. Freeman EW, June 769–773
Primary Care
Insomnia: a primary care perspective. Culpepper, Suppl 9, 14–17
Understanding and treating panic disorder in the primary care setting. Roy-Byrne, Suppl 4, 16–22
Prisoners of War
Posttraumatic stress disorder among Israeli ex–prisoners of war 18 and 30 years after release. Solomon Z, Aug 1031–1037
Prolactin
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. Melkersson, June 761–767
Psychiatry
Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. van Riemsdijk, Feb 199–204
Psychiatric genetics: a survey of psychiatrists' knowledge, opinions, and practice patterns. Finn, July 821–830
Psychoeducation
Improving treatment adherence in bipolar disorder through psychoeducation. Vieta, Suppl 1, 24–29
Peer-to-peer psychoeducation in schizophrenia: a new approach. Rummel, Dec 1581–1586
Psychomotor Function
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. Wingen, Apr 436–443
Psychopharmacology
Challenges and opportunities in teaching psychopharmacology during residency training [ASCP Corner]. Zisook, July 948
Gender differences in clinical psychopharmacology [ASCP Corner]. Clayton, Sept 1191
Neurobiology of depression: inroads to treatment and new drug discovery. Nemeroff, Suppl 7, 5–13
Cultural competence in clinical psychopharmacology [ASCP Corner]. Thompson, June 799
Psychosis
Addition of lamotrigine to clozapine in inpatients with chronic psychosis [letter]. Heck, Oct 1333
Development of subtle psychotic symptoms with memantine: a case report [letter]. Huey, May 658–659
Diagnostic stability 18 months after treatment initiation for first-episode psychosis. Schimmelmann, Oct 1239–1246
Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine [letter]. Chand, June 800–801
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Kraus, Dec 1565–1569
Relapsing paranoid psychosis as the first manifestation of pheochromocytoma [letter]. Benabarre, July 949–950
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases. Kim, July 887–893
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. Kozarić-Kovačić, July 922–927
Treatment-emergent psychosis with aripiprazole [letter]. Barnas, Oct 1339
Psychosomatic Medicine
Clinical domains of psychosomatic medicine. Fava, July 849–858
Psychotherapy
Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? Hollon, Apr 455–468
Psychotropic Drugs
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Sevy, July 839–843
Sexual function and dysfunction during treatment with psychotropic medications [ASCP Corner]. Balon, Nov 1488–1489
Public Health
Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. Guaiana, June 750–755
QTc Interval
QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. Mackin, Nov 1386–1391
Quality of Life
Male sexual dysfunction and quality of life in schizophrenia. Olfson, Mar 331–338
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. de Lima, July 831–838
Quetiapine
Diabetes mellitus during olanzapine and quetiapine treatment in Japan [letter]. Cohen D; Misawa reply, Feb 265–267
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Citrome, Dec 1513–1517
Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [letter]. Schutters, Apr 540–542
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick, May 638–641
Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [letter]. Galynker, Apr 544
Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Villeneuve, Oct 1298–1303
Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. Bogan, Jan 73–79
Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Bowden, Jan 111–121
Reduction of opioid-withdrawal symptoms with quetiapine. Pinkofsky, Oct 1285–1288
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach, Aug 1021–1030
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Kelly, Jan 80–84
Race
Factors associated with medication adherence in African American and white patients with bipolar disorder. Fleck, May 646–652
Rash
Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash [letter]. Bhatti, Nov 1490–1491
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. Ketter, May 642–645
Serious rash with lamotrigine after carbamazepine discontinuation: a case report [letter]. Subuh Surja, Mar 400–401
Reboxetine
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. Nelson, Nov 1409–1414
Recidivism
Recidivism in medication-noncompliant serious juvenile offenders with bipolar disorder. Dailey, Apr 477–484
Remission
Differences between minimally depressed patients who do and do not consider themselves to be in remission. Zimmerman, Sept 1134–1138
Pain predicts longer time to remission during treatment of recurrent depression. Karp, May 591–597
Predictors of remission after electroconvulsive therapy in unipolar major depression. Dombrovski, Aug 1043–1049
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Thase, Aug 974–981
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. Quitkin, June 670–676
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Gopal, Aug 1016–1020
Renal Function
Lithium dosing schedule and renal insufficiency [letter]. Smith; Lepkifker reply, Mar 396–397
Single versus multiple daily dosing of lithium: renal effects [letter]. Shammi; Lepkifker reply, Mar 398–399

Repetitive Transcranial Magnetic Stimulation
Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. Su, July 930–937
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial. Rossini, Dec 1570–1576
Long-term maintenance therapy for major depressive disorder with rTMS. O'Reardon, Dec 1525–1529
Underpowered repetitive transcranial magnetic stimulation might not be an effective antidepressant treatment [letter]. Kirov; Koerselman reply, Apr 543–544
Reproduction
Female reproductive cycle and obsessive-compulsive disorder. Labad, Apr 428–435
Restless Legs Syndrome
Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. Hornyak, Sept 1139–1145
Ribavirin
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Raison, Jan 41–48
Risk Factors
4-Fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. Saari, May 559–563
Risk factors for completed suicide in schizophrenia. Kuo, May 579–585
Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. Hawton, June 693–704
Risperidone
Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Brawman-Mintzer, Oct 1321–1325
Allergic reaction to depot risperidone but not to oral risperidone [letter]. Reeves, July 949
CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. de Leon, Jan 15–27
Double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Yağcıoğlu, Jan 63–72
Injection site pain with long-acting risperidone [letter]. Pinninti; Lindenmayer reply, May 656–657
Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [letter]. Galynker, Apr 544
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Kraus, Dec 1565–1569
Open-label risperidone for Asperger's disorder: negative symptom spectrum response. Rausch, Dec 1593–1598
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach, Aug 1021–1030
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li, June 736–743
Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases. Kim, July 887–893
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. Kozarić-Kovačić, July 922–927
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Gopal, Aug 1016–1020
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Kelly, Jan 80–84
Robins and Guze Criteria
Prepubertal and early adolescent bipolar I disorder: review of diagnostic validation by Robins and Guze criteria. Geller, Suppl 7, 21–28
Route of Administration
Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. Marchiaro, Nov 1423–1431
Safety
Safety issues with drug therapies for autism spectrum disorders. McCracken, Suppl 10, 32–37
Schizoaffective Disorder
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Brar, Feb 205–212
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Volavka, Nov 1362–1366
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick, May 638–641
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. Byerly, Aug 997–1001
Schizophrenia
Clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Brunstein, Feb 213–219
Commentary: suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Meltzer, Apr 530–533
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. Melkersson, June 761–767
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Citrome, Dec 1513–1517
Double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Yağcıoğlu, Jan 63–72
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Sevy, July 839–843
Economic burden of schizophrenia in the United States in 2002. Wu, Sept 1122–1129
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Brar, Feb 205–212
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Volavka, Nov 1362–1366
Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder [letter]. Chaves, Apr 542–543
4-Fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. Saari, May 559–563
High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. Lerner, Dec 1559–1564
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Evins, Sept 1184–1190
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick, May 638–641
Male sexual dysfunction and quality of life in schizophrenia. Olfson, Mar 331–338
Medical Comorbidity in Patients With Schizophrenia. Suppl 6, 1–46
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. Goff, Feb 183–194
Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. Marchiaro, Nov 1423–1431
Neurologic comorbidities in schizophrenia. Nasrallah, Suppl 6, 34–46
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Optimizing pharmacotherapy to maximize outcome in schizophrenia [Academic Highlights]. Jan 122–133
Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia [letter]. Tornatore; Kane reply, Nov 1493–1494
Overview of common medical comorbidities in patients with schizophrenia. Nasrallah, Suppl 6, 3–4
Peer-to-peer psychoeducation in schizophrenia: a new approach. Rummel, Dec 1581–1586
Predictors of everyday functioning among older Mexican Americans vs. Anglo-Americans with schizophrenia. Jeste, Oct 1304–1311
Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. Abel, June 781–789
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. de Lima, July 831–838

Recovery from schizophrenic psychoses within the Northern Finland 1966 Birth Cohort. Lauronen, Mar 375–383
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Dossenbach, Aug 1021–1030
Risk factors for completed suicide in schizophrenia. Kuo, May 579–585
Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. Cournos, Suppl 6, 27–33
Schizophrenia and comorbid metabolic disorders. Henderson, Suppl 6, 11–20
Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Green, Suppl 6, 21–26
Schizophrenia, antipsychotic drugs, and cardiovascular disease. Glassman, Suppl 6, 5–10
Schizophrenia patients with a history of severe violence differ from nonviolent schizophrenia patients in perception of emotions but not cognitive function. Silver, Mar 300–308
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Kelly, Jan 80–84
Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Tiihonen, Aug 1012–1015
Trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. Byerly, Aug 997–1001

Schizophrenia Spectrum Disorders
Associations of anxiety-related symptoms with reported history of childhood sexual abuse in schizophrenia spectrum disorders. Lysaker, Oct 1279–1284

Selective Serotonin Reuptake Inhibitors see also specific drugs
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Papakostas, Oct 1326–1330
Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. Posternak, June 705–707
Multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Fava, Jan 85–93
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Shelton, Oct 1289–1297
Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. Sharpley, Apr 450–454
Open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Iosifescu, Aug 1038–1042
Placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. DeBattista, July 844–848
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Thase, Aug 974–981
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Ball, Jan 94–99
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Demyttenaere, July 859–863

Self-Injurious Behavior
Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder [letter]. Pittenger, Nov 1492–1493

Sequenced Treatment Alternatives to Relieve Depression Study
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Novick, Aug 1002–1011
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Perlis, Feb 159–166

Serotonin Reuptake Inhibitors
Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. Bogan, Jan 73–79
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li, June 736–743

Sertraline
Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. Rocca, Mar 360–369
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial. Rossini, Dec 1570–1576
Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Murray, June 708–716
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. O'Connor, Mar 346–352
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Sir, Oct 1312–1320
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Ball, Jan 94–99
Sertraline treatment of pathological gambling: a pilot study. Saiz-Ruiz, Jan 28–33

Sexual Abuse
Associations of anxiety-related symptoms with reported history of childhood sexual abuse in schizophrenia spectrum disorders. Lysaker, Oct 1279–1284

Sexual Dysfunction
Antipsychotic-induced sexual dysfunction and the strength of the evidence [letter]. Rico-Villademoros; Olfson reply, Aug 1074–1076
Male sexual dysfunction and quality of life in schizophrenia. Olfson, Mar 331–338
Placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. DeBattista, July 844–848
Sexual function and dysfunction during treatment with psychotropic medications [ASCP Corner]. Balon, Nov 1488–1489
Weight gain, sexual dysfunction, and bupropion [letter]. Menaster; Zimmerman reply, Oct 1335–1339

Sexual Functioning
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Landén, Jan 100–106
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. Delgado, June 686–692

Sleep
Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. Benedetti, Dec 1536–1541
Excessive daytime sleepiness in young adults: a 20-year prospective community study. Hasler, Apr 521–529
Human circadian system in normal and disordered sleep. Richardson, Suppl 9, 3–9
Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. Hornyak, Sept 1139–1145
Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. Cohrs, Aug 989–996
Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. Sharpley, Apr 450–454
Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. Ancoli-Israel, Suppl 9, 24–30
Sleep and depression. Tsuno, Oct 1254–1269
Sleep: New Frontiers in Psychiatry and Primary Care. Suppl 9, 1–44

Smoking Cessation
Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. de Leon, Nov 1447–1455

Social Anxiety Disorder
Epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Grant BF, Nov 1351–1361
Randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Liebowitz, Feb 238–247
24-Week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Montgomery, Oct 1270–1278

Somatic Symptoms see Physical Symptoms

Somatoform Disorders
Relation between anger expression, depression, and somatic symptoms in depressive disorders and somatoform disorders. Koh, Apr 485–491
STAR*D see Sequenced Treatment Alternatives to Relieve Depression Study
Stroke
Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Murray, June 708–716
Substance Abuse
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. de Leon, Nov 1447–1455
Substance Use Disorders
Dissociative disorders among inpatients with drug or alcohol dependency. Karadag, Oct 1247–1253
Does recovery from substance use disorder matter in patients with bipolar disorder? Weiss, June 730–735
Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Compton, June 677–685
Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Green, Suppl 6, 21–26
Substance use disorders in individuals with body dysmorphic disorder. Grant JE, Mar 309–316
Suicide
ABCs of suicide [letter]. Freudenreich, Sept 1194–1195
Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. Garno, Mar 339–345
Clinical differences between suicidal and nonsuicidal depressed children and adolescents. Barbe, Apr 492–498
Clinical predictors of suicide in primary major depressive disorder. Coryell, Apr 412–417
Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. Modestin, Apr 534–538
Commentary: suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Meltzer, Apr 530–533
Differential modulation of cerebrospinal fluid neurotrophins in patients with atopic dermatitis who attempted suicide [letter]. Kimata, Sept 1193–1194
Risk factors for completed suicide in schizophrenia. Kuo, May 579–585
Suicidal ideation and attempts in bipolar I and II disorders. Valtonen, Nov 1456–1462
Suicidal ideation and suicide attempts in body dysmorphic disorder. Phillips, June 717–725
Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. Hawton, June 693–704
Switching
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Brown ES, June 756–760
Tachyphylaxis
Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. Posternak, June 705–707
Tachyphylaxis in unipolar major depressive disorder. Solomon, Mar 283–290
Tardive Dyskinesia
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Tenback, Sept 1130–1133
High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. Lerner, Dec 1559–1564
Historical comments on tardive dyskinesia: a neurologist's perspective. Paulson, Feb 260–264
Terrorism
Stress-related responses after 3 years of exposure to terror in Israel: are ideological-religious factors associated with resilience? Kaplan, Sept 1146–1154
Testosterone
Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. Shores, Jan 7–14
Texas Medication Algorithm Project
Texas implementation of medication algorithms update for treatment of bipolar I disorder [commentary]. Perlis, July 818–820
Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Suppes, July 870–886
Thyroid
Thyroid dysfunction during treatment with atypical antipsychotics [letter]. Greenspan, Oct 1334–1335
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Kelly, Jan 80–84
Tiagabine
Selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. Pollack, Nov 1401–1408
Titration
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. Ketter, May 642–645
Tobacco
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Evins, Sept 1184–1190
Topiramate
Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Tiihonen, Aug 1012–1015
Tourette's Disorder
Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. Toren, Apr 499–503
Tranylcypromine
Do antihypertensives make tranylcypromine safer? three case reports [letter]. Taylor, May 657–658
Trazodone
Review of the evidence for the efficacy and safety of trazodone in insomnia. Mendelson, Apr 469–476
Treatment Guidelines see Guidelines
Trichotillomania
Severe obsessive-compulsive disorder with and without comorbid hair pulling: comparisons and clinical implications. Stewart SE, July 864–869
Tricyclic Antidepressants
Interactions of cyclobenzaprine and tricyclic antidepressants [letter]. Rosenlicht, Jan 134–135
Triiodothyronine
Open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Iosifescu, Aug 1038–1042
Urea
Treatment of the polydipsia-hyponatremia syndrome with urea. Verhoeven, Nov 1372–1375
Vagus Nerve Stimulation (VNS)
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. Nahas, Sept 1097–1104
Valproate
Carnitine levels in valproic acid–treated psychiatric patients: a cross-sectional study. Moreno, May 555–558
Case of delirium and subsequent pancytopenia associated with the oral loading of valproic acid [letter]. Chae, June 801–802
Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. Shulman, Apr 424–427
Venlafaxine
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial. Rossini, Dec 1570–1576
Randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Liebowitz, Feb 238–247
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Sir, Oct 1312–1320
Violence
Schizophrenia patients with a history of severe violence differ from nonviolent schizophrenia patients in perception of emotions but not cognitive function. Silver, Mar 300–308
War
Posttraumatic stress disorder among Israeli ex–prisoners of war 18 and 30 years after release. Solomon Z, Aug 1031–1037
Weight
Behavioral treatment of obesity in patients taking antipsychotic medications. Kalarchian, Aug 1058–1063
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: response to consensus statement [letter]. Citrome, Aug 1073–1074
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Brar, Feb 205–212

Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain [letter]. Sharpe; Ganguli reply, July 951–952
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Andersen, Nov 1468–1476
Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Susce, Feb 167–173
Obesity and mood disorders: the complex problem of insight [letter]. Ravaldi, Feb 265
Weight changes in postpartum women with remitted depression. Gracious, Mar 291–293
Weight gain and antipsychotics [letter]. Mackin; Kane reply, July 950–951
Weight gain, sexual dysfunction, and bupropion [letter]. Menaster; Zimmerman reply, Oct 1335–1339
Women
Empowering women to collaborate in their mental health care. Freeman MP, June 768
Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. Morgan, June 774–780
Female reproductive cycle and obsessive-compulsive disorder. Labad, Apr 428–435
Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. McKenna, Apr 444–449
Preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. Freeman EW, June 769–773
Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. Abel, June 781–789
Prevalence of maternal depressive symptoms in low-income Hispanic women. Chaudron, Apr 418–423
Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Diav-Citrin, Mar 317–322
Weight changes in postpartum women with remitted depression. Gracious, Mar 291–293
World Trade Center Disaster
Dissociation and posttraumatic stress 1 year after the World Trade Center disaster: follow-up of a longitudinal survey. Simeon, Feb 231–237
Yale-Brown Obsessive Compulsive Scale
Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. Tolin, Dec 1550–1558
Yi-Gan San
Effects of the traditional Chinese herbal medicine *Yi-Gan San* for cholinesterase inhibitor–resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies [letter]. Iwasaki, Dec 1612–1613
Randomized, observer-blind, controlled trial of the traditional Chinese medicine *Yi-Gan San* for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. Iwasaki, Feb 248–252
Ziprasidone
African patient with ziprasidone intolerance [letter]. Hein, June 800
Applying parsimony to "An African Patient With Ziprasidone Intolerance" [letter]. Anders; Hein reply, Nov 1491
Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. Cohrs, Aug 989–996
New onset of diabetes mellitus with ziprasidone: a case report [letter]. Sánchez-Barranco, Feb 268–269
Retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. Greco, July 928–929
Zonisamide
New onset of diabetes mellitus with ziprasidone: a case report [letter]. Sánchez-Barranco, Feb 268–269
Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. McElroy, May 617–624
Preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. Anand, Feb 195–198

The Journal of Clinical Psychiatry

CALL FOR PAPERS

www.PSYCHIATRIST.com/authors/call.htm

FOCUS ON ALZHEIMER'S DISEASE AND RELATED DISORDERS

To encourage scientific studies of Alzheimer's disease, promote the optimal care of patients, and help keep the psychiatric community informed of the latest scientific and clinical developments, the *Journal* invites authors to submit high-quality research manuscripts and scholarly reviews that "Focus on Alzheimer's Disease and Related Disorders."

In addition to the randomized clinical trials of putative treatments for cognitive and noncognitive symptoms for which the *Journal* is especially well known, authors are encouraged to submit manuscripts capitalizing on the use of genomic, proteomic, and brain imaging tools of growing importance to the study of Alzheimer's disease and other psychiatric disorders. Other topics of interest include any biological, psychosocial, economic, or health services aspect of Alzheimer's disease. We also invite manuscripts related to the scientific understanding, differential diagnosis, early detection and tracking, treatment, and prevention of Alzheimer's disease and, indeed, any research article or scholarly review of scientific importance or clinical relevance to the study of Alzheimer's disease, mild cognitive impairment, and related disorders. All submitted manuscripts will undergo the *Journal*'s usual editorial evaluation and peer review.

Our electronic submission system is easy to use and facilitates rapid turnaround. Please consult the *Journal*'s Information for Authors for guidelines on manuscript preparation at www.psychiatrist/authors. Accepted articles will be published as part of our Focus on Alzheimer's Disease and Related Disorders series.

THE JOURNAL OF CLINICAL PSYCHIATRY

The Journal of Clinical Psychiatry

Author Index to Volume 66: January 2005 Through December 2005

Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. May 633–637

Abel KM, Webb RT, Salmon MP, Wan MW, Appleby L. Prevalence and predictors of parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and baby psychiatric care in England. June 781–789

Aboujaoude EN see Koran LM

Abramowitz JS see Tolin DF

Ader M see Bergman RN

Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. Mar 294–299

Adli M see Baethge C

Aer J see Tiihonen J

Agarwalla P see Modestin J

Aggarwal J see Wu EQ

Aguilar J see Dossenbach M

Ahl J see Hoffmann VP

Ajdacic V see Hasler G

Akdede BBK see Yağcıoğlu AEA

Akiskal HS, Benazzi F. Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. July 914–921

Alarcon AM see Ketter TA

Albert A see Demyttenaere K

Alméras N, Després J-P, Villeneuve J, Demers M-F, Bouchard R-H. Reply to Karagianis JL: Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics [letter]. Jan 138

Alonso P see Labad J

Alpert JE see Iosifescu DV; Papakostas GI

Alptekin K see Yağcıoğlu AEA

Altshuler LL see Keck PE Jr; McElroy SL; Post RM; Suppes T

Alvir J see Sevy S

Aman MG. Treatment planning for patients with autism spectrum disorders. Suppl 10, 38–45

American Indian Service Utilization, Psychiatric Epidemiology, Risk and Protective Factors Project (AI-SUPERPFP)/Healthy Ways Research Teams see Gnanadesikan M

Anand A, Bukhari L, Jennings SA, Lee C, Kamat M, Shekhar A, Nurnberger JI Jr, Lightfoot J. Preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. Feb 195–198

Anand S see Chand PK

Ananth J. Reply to Carroll BT, Lee JWY: Catatonia is a risk factor for neuroleptic malignant syndrome [letter] 2004 Dec 1722–1723. Reply. Jan 134

Ancoli-Israel S. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. Suppl 9, 24–30

Anders JL. Applying parsimony to "An African Patient With Ziprasidone Intolerance" [letter with reply]. Nov 1491

Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Nov 1468–1476

Anderson G see Shulman KI

Andretta M see Guaiana G

Angst J see Hasler G

Appleby L see Abel KM

Appleton WS. Review of Castle DJ, Murray R (eds): *Marijuana and Madness: Psychiatry and Neurobiology*. Aug 1080

Arai H see Iwasaki K

Arango-Dávila C see Dossenbach M

Arnon J see Diav-Citrin O

Arvilommi P see Valtonen H

Åsberg M see Murray V

Asnis G see Liebowitz MR

Assunção S see Dossenbach M

Attenburrow MEJ see Sharpley AL

Attiullah N see Zimmerman M

Axelson DA see Barbe RP

Baca-Garcia E see Diaz-Sastre C

Badamath S see Reddy YCJ

Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghöfer A, Müller-Oerlinghausen B, Bschor T, Adli M, Bauer M. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. Feb 174–182

Balasubramani GK see Novick JS

Baldessarini RJ see Baethge C

Ball DE see Wu EQ

Ball MP see McKee JR

Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Jan 94–99

Ballard CG see Aarsland D

Ballmaier M see Lavretsky H

Balon R. Sexual function and dysfunction during treatment with psychotropic medications [ASCP Corner]. Nov 1488–1489

Barbarich-Marsteller NC, Kaye WH. Reply to Menaster M: Use of olanzapine in anorexia nervosa [letter]. May 655–656

Barbe RP, Williamson DE, Bridge JA, Birmaher B, Dahl RE, Axelson DA, Ryan ND. Clinical differences between suicidal and nonsuicidal depressed children and adolescents. Apr 492–498

Barbini B see Benedetti F

Barboni E see Ravaldi C

Barbui C see Guaiana G

Barnas ME, Hussain N, Petrides G. Treatment-emergent psychosis with aripiprazole [letter]. Oct 1339

Bartfai A see Murray V

Bartholomä A see Hein J

Basson BR see Treuer T

Bauer M see Baethge C

Baxter LR Jr see Li X

Baymiller S see Zimmerman M

Beals J see Gnanadesikan M

Beard L see Brown ES

Becker OV see Ketter TA

Beer R see Kirov G

Begley AE see Dombrovski AY

Belger MA see Tenback DE

Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. Sept 1111–1115

Belmaker RH see Nemets B; Osher Y

Benabarre A, Bosch X, Plana MT, Lecube A, Vieta E, Cirera E, Valdés M. Relapsing paranoid psychosis as the first manifestation of pheochromocytoma [letter]. July 949–950

Benabarre A see Vieta E

Benazzi F. Possible bipolar nature of irritability in major depressive disorder [letter with reply]. Aug 1072

Benazzi F see Akiskal HS

Benedetti F, Barbini B, Fulgosi MC, Colombo C, Dallaspezia S, Pontiggia A, Smeraldi E. Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. Dec 1536–1541

Bentler SE, Hartz AJ, Kuhn EM. Prospective observational study of treatments for unexplained chronic fatigue. May 625–632

Berger M see Hornyak M

Berggren A-L see Murray V

Berghöfer A see Baethge C

Bergman J, Dwolatzky T, Brettholz I, Lerner V. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. Jan 107–110

Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. Apr 504–514

Berlowitz SL see Zimmerman M

Bernabei R see Liperoti R; Onder G

Berner W see Briken P

Bernstein CA. Review of Sadock BJ, Sadock VA, Jones RM: *Kaplan and Sadock's Study Guide and Self-Examination Review in Psychiatry, Seventh Edition*. Mar 402

Berry S see Brar JS
Bersudsky Y see Nemets B; Osher Y
Besset A see Tsuno N
Bhatia R see Rausch JL
Bhatti MA, Zander J, Reeve E. Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash [letter]. Nov 1490–1491
Biederman J see Wilens TE
Bierer M see Goff DC
Biggs MM see Novick JS
Birmaher B see Barbe RP
Birnbaum HG see Wu EQ
Black D see McElroy SL
Black KJ. Review of Lisanby SH (ed): *Brain Stimulation in Psychiatric Treatment.* Nov 1496
Blacker D see Finn CT
Blanco C see Grant BF; Saiz-Ruiz J
Blansjaar BA see Kho KH
Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. Suppl 8, 30–40
Blumner KH see O'Reardon JP
Bodfish JW see McKee JR
Boerescu D see Zimmerman M
Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. Jan 73–79
Bogetto F see Bellino S; Marchiaro L; Rocca P
Boland RJ see Zimmerman M
Borba CP see Henderson DC
Borisov AS see Raison CL
Bosch X see Benabarre A
Bose A see Davidson JRT
Bothmer J see Wingen M
Bouchard R-H see Alméras N
Boulenger J-P see Montgomery SA
Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Suppl 3, 12–19
Bowden CL. Introduction: the burden of bipolar depression. Suppl 5, 3–4
Bowden CL. Treatment options for bipolar depression. Suppl 1, 3–6
Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vågerö M, Svensson K. Randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Jan 111–121
Bowden CL see Suppes T; Weiss RD; Yatham LN
Bradwejn J see Liebowitz MR
Brannan SK see Delgado PL
Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Feb 205–212
Brar JS see Ganguli R
Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Oct 1321–1325
Brecher M see Bowden CL
Breier A see de Lima MS
Brettholz I see Bergman J
Bridge JA see Barbe RP
Briggs SD see Keck PE Jr; Shelton RC
Briken P, Hill A, Berner W. Reply to Saleh FM: Issues to consider in the assessment and treatment of paraphilic patients [letter]. June 803
Broadwell SD see Raison CL
Bronskill S see Shulman KI
Brotzge KE see Subuh Surja AA
Brown C see Pollack MH
Brown ES, Jeffress J, Liggin JDM, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. June 756–760
Brown FW. Review of Roose SP, Sackeim HA (eds): *Late-Life Depression.* Apr 545
Brown FW see Greco KE
Bruce SE see Otto MW
Brunner F see Papassotiropoulos A
Brunstein MG, Ghisolfi ES, Ramos FLP, Lara DR. Clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. Feb 213–219
Bschor T see Baethge C
Bucardo J see Jeste ND
Bukhari L see Anand A
Bullock KD see Koran LM
Burkholder P. Review of Roukema RW: *What Every Patient, Family, Friend, and Caregiver Needs to Know About Psychiatry, 2nd ed.* Jan 139
Burn D see Aarsland D
Burnham DB see Sheehan DV
Burns AM see Papakostas GI
Burt T see Sir A
Bushey MP see Lamberti JS
Buysse DJ see Hasler G
Byerly MJ, Fisher R, Carmody T, Rush AJ. Trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. Aug 997–1001
Byrne NM see Sharpe J-K
Bystritsky A see Bogan AM
Calabrese JR, Elhaj O, Gajwani P, Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. Suppl 5, 26–33
Calabrese JR see Gao K; Suppes T; Weiss RD; Yatham LN
Calandre EP see Rico-Villademoros F
Calvarese P see Rocca P
Campbell FA see Pinkofsky HB
Capapey J see Vieta E
Capuron L see Raison CL
Carmody T see Byerly MJ
Caro O see Dossenbach M
Carpenter I see Onder G
Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. Oct 1234–1238
Carr BM see Rausch JL
Carson WH see Olfson M; Volavka J
Case M see Keck PE Jr; Shelton RC
Castera L see Constant A
Catananti C see Onder G
Cather C see Evins AE; Goff DC; Henderson DC
Cebollada A see Diaz-Sastre C
Chae B-J, Kang B-J. Case of delirium and subsequent pancytopenia associated with the oral loading of valproic acid [letter]. June 801–802
Chand PK, Anand S, Murthy P. Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine [letter]. June 800–801
Chandler RA see Ketter TA
Chang K see Saxena K
Chaudron LH, Kitzman HJ, Peifer KL, Morrow S, Perez LM, Newman MC. Prevalence of maternal depressive symptoms in low-income Hispanic women. Apr 418–423
Chaves MPR, Crippa JAS, Morais SL, Zuardi AW. Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder [letter]. Apr 542–543
Chelminski I see Zimmerman M
Chen C-C see Chiu C-C; Kuo C-J; Tsai S-Y
Chen JJ, Swope DM. Case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A [letter]. Feb 267–268
Cheron DM see Shedlack KJ
Chiang C see Liperoti R
Chiles C. Review of Wyszynski AA, Wyszynski B (eds): *Manual of Psychiatric Care for the Medically Ill.* Dec 1618
Chiu C-C, Huang S-Y, Chen C-C, Su K-P. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder [letter]. Dec 1613–1614
Choi S-K see Kim CY
Chou SP see Grant BF
Choung HW see Koran LM
Christi JA see Roy-Byrne PP
Chuong HW see Bogan AM
Cirera E see Benabarre A
Citrome L, Jaffe A, Levine J, Lindenmayer J-P. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Dec 1513–1517
Citrome L, Volavka J. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: response to consensus statement [letter]. Aug 1073–1074
Citrome L see Volavka J
Citrome LL. Antipsychotic medication and diabetes mellitus [letter with reply]. Mar 395
Clark S see Wilens TE
Clayton AH. Gender differences in clinical psychopharmacology [ASCP Corner]. Sept 1191
Clementi M see Diav-Citrin O
Clemow DB see Andersen SW
Coccaro EF, Posternak MA, Zimmerman M. Prevalence and features of intermittent explosive disorder in a clinical setting. Oct 1221–1227
Cohen D. Diabetes mellitus during olanzapine and quetiapine treatment in Japan [letter with reply]. Feb 265–266
Cohen D, Stolk RP. Reply to Citrome: Antipsychotic medication and diabetes mellitus [letter]. Mar 395
Cohen D see Toren P

Cohen H see Kaplan Z
Cohen LJ see Galynker I
Cohen ST, Rulf D, Pies R. Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients [letter]. Jan 135–136
Cohrs S, Meier A, Neumann A-C, Jordan W, Rüther E, Rodenbeck A. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. Aug 989–996
Coles ME see Phillips KA
Collins DM see Hoffmann VP
Colliver JD see Compton WM
Colombo C see Benedetti F
Comes M see Vieta E
Compton WM, Conway KP, Stinson FS, Colliver JD, Grant BF. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. June 677–685
Conley RR see Kelly DL
Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JRT. Use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. Jan 49–51
Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, Henry C. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Aug 1050–1057
Conus P see Schimmelmann BG
Conway KP see Compton WM
Cook A see Kraus JE
Cook IA see Morgan ML; Novick JS
Copeland PM see Goff DC; Henderson DC
Corbari L see Guaiana G
Corey KB see Fleck DE
Coric V see Pittenger C
Corral M see Misri S
Correll CU. Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? [ASCP Corner] Oct 1331–1332
Correll CU. Real-life dosing with second-generation antipsychotics [ASCP Corner] Dec 1611–1612
Corya SA see Andersen SW; Keck PE Jr; Shelton RC
Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. Apr 412–417
Coryell W see Solomon DA
Costa AM see de Lima MS
Costea GO see Lamberti JS
Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. Suppl 6, 27–33
Couzigou P see Constant A
Cowen PJ see Sharpley AL
Crilly JF see Lamberti JS
Crippa JAS see Chaves MPR
Crismon ML see Suppes T
Crockford DN, White WD. Mirtazapine for alcohol dependence: a case report [letter]. Apr 540
Culhane MA see Evins AE
Culpepper L. Insomnia: a primary care perspective. Suppl 9, 14–17
Cutler AJ see Weisler RH
Czobor P see Volavka J
Dahl RE see Barbe RP
Dailey LF, Townsend SW, Dysken MW, Kuskowski MA. Recidivism in medication-noncompliant serious juvenile offenders with bipolar disorder. Apr 477–484
Daley DC see Pinkofsky HB
Dallaspezia S see Benedetti F
Daniels W see Lochner C
Dantzer R see Constant A
Dar R see Hermesh H
D'Avanzo B see Guaiana G
Davidson JRT, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Nov 1441–1446
Davidson JRT see Connor KM
Davies CA see Quitkin FM
Davila-Fraga W see Jeste ND
Davis LW see Lysaker PH
Dawson DA see Grant BF
DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. Placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. July 844–848
DeBattista C see Fava M
De Bruyckere K see Demyttenaere K
Decaux G see Verhoeven A
Deckersbach T see Evins AE; Otto MW
de Groot IW see Heck AH
de Haan E see van Oppen P
de Jesus Mari J see de Lima MS
Dekel R see Solomon Z
de Ledinghen V see Constant A
de Leon J, Susce MT, Diaz FJ, Rendon DM, Velásquez DM. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. Nov 1447–1455
de Leon J, Susce MT, Pan R-M, Fairchild M, Koch WH, Wedlund PJ. CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. Jan 15–27
de Leon J see Diaz-Sastre C; Susce MT
Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. June 686–692
de Lima MS, de Jesus Mari J, Breier A, Costa AM, de Sena EP, Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. July 831–838
de Lissovoy G see Matza LS
Deliyannides D see Quitkin FM
Demers M-F see Alméras N
Demotes-Mainard J see Constant A
Demyttenaere K, Albert A, Mesters P, Dewé W, De Bruyckere K, Sangeleer M. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? July 859–863
Dennehy EB see Suppes T
Denys D see Vulink NCC
Denys DAJP see Tenneij NH
DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter with reply]. Mar 396
de Sena EP see de Lima MS
Deshpande S see Reddy YCJ
Després J-P see Alméras N
Detke MJ see Delgado PL
Deveney C see Otto MW
Dewé W see Demyttenaere K
Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Mar 317–322
Diav-Citrin O see McKenna K
Diaz FJ see de Leon J; Susce MT
Diaz-Sastre C, Perez-Rodriguez MM, Cebollada A, Saiz Ruiz J, Baca-Garcia E, de Leon J. Cholesterol and lithium levels were correlated but serum HDL and total cholesterol levels were not associated with current mood state in bipolar patients [letter]. Mar 399–400
Diefenbach GJ see Tolin DF
Dietz MB see Lamberti JS
Diez T see Saiz-Ruiz J
Ditterline JW see Wilens TE
Dombrovski AY, Mulsant BH, Haskett RF, Prudic J, Begley AE, Sackeim HA. Predictors of remission after electroconvulsive therapy in unipolar major depression. Aug 1043–1049
Dossenbach M, Arango-Dávila C, Ibarra HS, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Aug 1021–1030
Douaihy AB see Pinkofsky HB
D'Souza RF see Sir A
D'Souza SM see Reddy YCJ
Duckworth K see Goff DC
Dunayevich E see Karagianis JL
Dunlop BW see Ninan PT
Dunn E see Kirov G
Dunner DL. Atypical antipsychotics: efficacy across bipolar disorder subpopulations. Suppl 3, 20–27
Dürr-Pal N see Montgomery SA
Dustin IH see Huey ED
Dwolatzky T see Bergman J
Dysken MW see Dailey LF
Edwards J see Schimmelmann BG
Eerdekens E see Lindenmayer J-P
Eerdekens M see Lindenmayer J-P
Eich D see Hasler G
Einarson A see McKenna K
Elhaj O see Calabrese JR; Gao K

Elliott M see Koran LM
Ellison JM. Review of Salzman C (ed.): *Clinical Geriatric Psychopharmacology, 4th ed.* June 805–806
El-Mallakh RS see Subuh Surja AA
El Sheshai A see Simpson GM
Emslie GJ, Ryan ND, Wagner KD. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. Suppl 7, 14–20
Endicott J see Solomon DA
Erhart SM, Young AS, Marder SR, Mintz J. Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. Aug 968–973
Erickson CA see McDougle CJ
Erkiran M see Karadag F
Erman MK. Therapeutic options in the treatment of insomnia. Suppl 9, 18–23
Eronen M see Tiihonen J
Ertuğrul A see Yağcıoğlu AEA
Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. Sept 1184–1190
Evins AE see Goff DC; Henderson DC
Evren C see Karadag F
Faggiano F see Rocca P
Fairchild M see de Leon J
Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. Nov 1392–1400
Fava GA, Sonino N. Clinical domains of psychosomatic medicine. July 849–858
Fava GA see Mangelli L
Fava M, Thase ME, DeBattista C. Multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Jan 85–93
Fava M see Iosifescu DV; Papakostas GI; Perlis RH
Fawzy W see Simpson GM
Fay C see Grant JE; Phillips KA
Fayek M see Simpson GM
Fenton WS see Lauronen E
Ferdousi T see Freeman EW
Findling RL. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. Suppl 10, 26–31
Findling RL. Review of Litz BT (ed): *Early Intervention for Trauma and Traumatic Loss.* Oct 1340
Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. Suppl 7, 29–40
Finn CT, Wilcox MA, Korf BR, Blacker D, Racette SR, Sklar P, Smoller JW. Psychiatric genetics: a survey of psychiatrists' knowledge, opinions, and practice patterns. July 821–830
Finne-Soveri H see Onder G
Fischmann D see Simon NM
Fisher R see Byerly MJ
Fleck DE, Keck PE Jr, Corey KB, Strakowski SM. Factors associated with medication adherence in African American and white patients with bipolar disorder. May 646–652
Flournoy JM Jr see Li X
Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. Suppl 10, 3–8
Fossey M see Weiss RD
Fraguas R see Perlis RH
Frank E see Karp JF
Franz B see Koran LM
Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. Preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. June 769–773
Freeman MP. Empowering women to collaborate in their mental health care. June 768
Freudenreich O. ABCs of suicide [letter]. Sept 1194–1195
Freudenreich O see Evins AE; Goff DC; Henderson DC
Friedman M see Zimmerman M
Frye MA see McElroy SL; Post RM
Fujii M see Iwasaki K
Fujii Y see Misawa F
Fujiwara H see Iwasaki K
Fulgosi MC see Benedetti F
Furukawa K see Iwasaki K
Gadde KM see Connor KM
Gajwani P see Calabrese JR; Gao K
Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [letter]. Apr 544
Gambassi G see Liperoti R; Onder G
Gamel NN see Koran LM
Gamma A see Hasler G
Ganguli R, Brar JS. Reply to Sharpe J-K: Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain [letter]. July 952
Ganguli R see Brar JS
Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. Nov 1376–1385
Gao K see Calabrese JR
Garbis H see Diav-Citrin O
Garno JL, Goldberg JF, Ramirez PM, Ritzler BA. Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. Mar 339–345
Garver DL. Review of Healy D: *The Creation of Psychopharmacology.* Oct 1340
Garza M see Brown ES
Gatton MJ see Lysaker PH
Gelenberg AJ. Another year passes [editorial]. Dec 1508–1512
Gelenberg AJ. Funding, conflicts, and paradigms [editorial]. May 554
Geller B, Tillman R. Prepubertal and early adolescent bipolar I disorder: review of diagnostic validation by Robins and Guze criteria. Suppl 7, 21–28
George MS see Nahas Z
George T see Sir A
Gharabawi G see Greenspan A
Ghisolfi ES see Brunstein MG
Gill S see Shulman KI
Giordani S see Rossini D
Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. Suppl 6, 5–10
Glassman AH see O'Connor CM
Glick I see Zisook S
Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. May 638–641
Gnanadesikan M, Novins DK, Beals J, for the American Indian Service Utilization, Psychiatric Epidemiology, Risk and Protective Factors Project (AI-SUPERPFP)/ Healthy Ways Research Teams. Relationship of gender and trauma characteristics to posttraumatic stress disorder in a community sample of traumatized Northern Plains American Indian adolescents and young adults. Sept 1176–1183
Goddard AW see Ball SG
Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. Feb 183–194
Goff DC see Evins AE; Henderson DC
Göğüş A see Yağcıoğlu AEA
Goikolea JM see Vieta E
Goldberg DA. Review of Stein DJ (ed.): *The Clinical Manual of Anxiety Disorders.* Feb 271
Goldberg DA see Zisook S
Goldberg JF see Garno JL
Goldman SR see Jeste ND
Goldstein JM see Yatham LN
Goldstein RB see Grant BF
Golshan S see Jeste ND
Gómez MM see Saiz-Ruiz J
Goodman C see Silver H
Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Aug 1016–1020
Gracious BL, Hanusa BH, Wisner KL, Peindl KS, Perel JM. Weight changes in postpartum women with remitted depression. Mar 291–293
Grandi S see Mangelli L
Grannemann BD see Trivedi MH
Grant BF, Hasin DS, Blanco C, Stinson FS, Chou SP, Goldstein RB, Dawson DA, Smith S, Saha TD, Huang B. Epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Nov 1351–1361
Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B. Prevalence, correlates, and comorbidity of bipolar I disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Oct 1205–1215
Grant BF see Compton WM; Petry NM
Grant JE. Clinical characteristics and psychiatric comorbidity in males with exhibitionism. Nov 1367–1371
Grant JE, Menard W, Pagano ME, Fay C, Phillips KA. Substance use disorders in individuals with body dysmorphic disorder. Mar 309–316

Grassi L see Mangelli L
Grebchenko Y see Galynker I
Greco KE, Tune LE, Brown FW, Van Horn WA. Retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. July 928–929
Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Suppl 6, 21–26
Green MF see Evins AE
Greenberg J see Simeon D
Greeno CG see Kalarchian MA
Greenspan A, Gharabawi G, Kwentus J. Thyroid dysfunction during treatment with atypical antipsychotics [letter]. Oct 1334–1335
Gregor A see Hein J
Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. Suppl 9, 31–41
Groman A see Lamberti JS
Gross-Isseroff R see Hermesh H
Grunze H. Reevaluating therapies for bipolar depression. Suppl 5, 17–25
Grunze H see Bowden CL; McElroy SL; Post RM; Yatham LN
Guaiana G, Andretta M, Corbari L, Mirandola M, Sorio A, D'Avanzo B, Barbui C. Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. June 750–755
Gulanski B see Sernyak MJ
Gunduz-Bruce H see Sevy S
Haas GL see Kalarchian MA
Hafizi S see Sharpley AL
Hahn AM see Pinkofsky HB
Haight BR see Thase ME
Hallikainen T see Tiihonen J
Halonen P see Tiihonen J
Hammerness PG see Wilens TE
Hansen W-P see Rummel CB
Hanusa BH see Gracious BL
Hardy S see Volavka J
Hargrave R. Review of Bender S, Messner E: *Becoming a Therapist: What Do I Say, and Why?* Jan 139
Harriett AE see Thase ME
Harrison DJ see O'Connor CM
Harriss L see Hawton K
Hartz AJ see Bentler SE
Hasin DS see Grant BF
Haskett RF see Dombrovski AY
Hasler G, Buysse DJ, Gamma A, Ajdacic V, Eich D, Rössler W, Angst J. Excessive daytime sleepiness in young adults: a 20-year prospective community study. Apr 521–529
Haw C see Hawton K
Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. June 693–704
Hayden DL see Henderson DC
Heck AH, de Groot IW, van Harten PN. Addition of lamotrigine to clozapine in inpatients with chronic psychosis [letter]. Oct 1333
Heeth WL see McKee JR
Hein J. Reply to Anders JL: Applying parsimony to "An African Patient With Ziprasidone Intolerance" [letter]. Nov 1491–1492
Hein J, Gregor A, Bartholomä A, Heinz A, Juckel G. African patient with ziprasidone intolerance [letter]. June 800
Heinz A see Hein J
Helbig A see Rummel CB
Hemmings SMJ see Lochner C
Henderson DC. Schizophrenia and comorbid metabolic disorders. Suppl 6, 11–20
Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Sept 1116–1121
Henderson DC see Evins AE; Goff DC
Hennen J see Shedlack KJ
Henry C see Constant A
Herman SM see Lysaker PH
Hermesh H, Gross-Isseroff R, Konas S, Shiloh R, Weizman A, Marom S, Dar R. Reply to Teunisse RJ: Problems in assessing musical hallucinations [letter]. Jan 136–137
Hill A see Briken P
Hills AP see Sharpe J-K
Hiremath AS see Shetti CN
Hirschfeld RMA. Introduction: the role of atypical antipsychotics in the treatment of bipolar disorder. Suppl 3, 3–4
Hirschfeld RMA see Suppes T
Hirschowitz J, Simon A. Review of Simon RI: *Assessing and Managing Suicide Risk: Guidelines for Clinically Based Risk Management.* June 804–805
Hock C see Papassotiropoulos A
Hoffmann VP, Ahl J, Meyers A, Schuh L, Shults KS, Collins DM, Jensen L. Wellness intervention for patients with serious and persistent mental illness. Dec 1577–1580
Högberg P see Landén M
Hollander E see Simeon D
Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ. Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? Apr 455–468
Hong J-P see Kim CY
Hopwood M see Sir A
Hornyak M, Kopasz M, Berger M, Riemann D, Voderholzer U. Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. Sept 1139–1145
Hotopf M see de Lima MS
Houck P see Karp JF
Huang B see Grant BF
Huang C-C see Su T-P
Huang S-Y see Chiu C-C
Huey ED, Dustin IH, Overman GP, Mirza N, Sunderland T. Development of subtle psychotic symptoms with memantine: a case report [letter]. May 658–659
Husain MM see Nahas Z
Hussain N see Barnas ME
Hyvärinen S see Tiihonen J
Ibáñez A see Saiz-Ruiz J
Ibarra HS see Dossenbach M
Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M. Open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Aug 1038–1042
Isakov V see Silver H
Isohanni M see Lauronen E
Isohanni MK see Saari KM
Isometsä ET see Melartin TK; Valtonen H
Iwasaki K, Maruyama M, Tomita N, Furukawa K, Nemoto M, Fujiwara H, Seki T. Effects of the traditional Chinese herbal medicine *Yi-Gan San* for cholinesterase inhibitor–resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies [letter]. Dec 1612–1613
Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N, Tanji H, Fujiwara H, Seki T, Fujii M, Arai H, Sasaki H. Randomized, observer-blind, controlled trial of the traditional Chinese medicine *Yi-Gan San* for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. Feb 248–252
Iyengar MK see Sheehan DV
Jackson WT see Li X
Jacobson IM see Raison CL
Jaffe A see Citrome L
Jarrett RB see Hollon SD
Järvelin M-R see Saari KM
Jayathilake K see Yağcıoğlu AEA
Jefferson JW. It looks like "bradyphylaxis" to me [letter with reply]. Aug 1076
Jeffress J see Brown ES
Jenike MA see Stewart SE
Jennings SA see Anand A
Jensen L see Hoffmann VP
Jeste DV see Jeste ND
Jeste ND, Moore DJ, Goldman SR, Bucardo J, Davila-Fraga W, Golshan S, Jeste DV, Patterson TL. Predictors of everyday functioning among older Mexican Americans vs. Anglo-Americans with schizophrenia. Oct 1304–1311
Jiménez S see Labad J
Joffe G see Tiihonen J
Johnson ME see Rausch JL
Johnson MW see Griffiths RR
Jones M see Bowden CL
Jones PB see Lauronen E
Joo YH see Kim CY
Jordan W see Cohrs S
Joseph DI. Review of Flem L: *Freud the Man: An Intellectual Biography.* May 660–661
Juckel G see Hein J
Judd LL see Solomon DA
Kalali AH see Weisler RH
Kalarchian MA, Marcus MD, Levine MD, Haas GL, Greeno CG, Weissfeld LA, Qin L. Behavioral treatment of obesity in patients taking antipsychotic medications. Aug 1058–1063
Kamat M see Anand A
Kamin R see Kaplan Z
Kandavel T see Reddy YCJ; Shetti CN

Kane JM. Reading reports of clinical trial results [ASCP Corner]. May 653
Kane JM. Reply to Mackin P: Weight gain and antipsychotics [letter]. July 951
Kane JM. Reply to Tornatore FL: Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia [letter]. Nov 1494
Kang B-J see Chae B-J
Kaplan Z, Matar MA, Kamin R, Sadan T, Cohen H. Stress-related responses after 3 years of exposure to terror in Israel: are ideological-religious factors associated with resilience? Sept 1146–1154
Kaptsan A see Lerner V
Karadag F, Sar V, Tamar-Gurol D, Evren C, Karagoz M, Erkiran M. Dissociative disorders among inpatients with drug or alcohol dependency. Oct 1247–1253
Karagianis JL, Dunayevich E. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics [letter with reply]. Jan 137
Karagoz M see Karadag F
Karp JF, Scott J, Houck P, Reynolds CF III, Kupfer DJ, Frank E. Pain predicts longer time to remission during treatment of recurrent depression. May 591–597
Kashyap K see Shetti CN
Kato M see Oda K
Katona C see Onder G
Kaye WH see Barbarich-Marsteller NC
Keck PE Jr. Reply to Treuer: Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania? [letter] Oct 1334
Keck PE Jr. Role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. Suppl 3, 5–11
Keck PE Jr, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. May 611–616
Keck PE Jr see Fleck DE; McElroy SL; Perlis RH; Post RM; Weisler RH
Keller MB. Issues in treatment-resistant depression. Suppl 8, 5–12
Keller MB see Solomon DA
Kelly DI see Suppes T
Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Jan 80–84
Kendrick E see DeBattista C
Kessler RC see Wu EQ
Ketter TA, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, O'Keeffe CM, Schumacher MR. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. May 642–645
Ketter TA see Keck PE Jr; Weisler RH; Suppes T
Keuthen NJ see Stewart SE
Khalid N see Kirov G
Khan A see Galynker I
Khanzode L see Saxena K
Kho KH, Zwinderman AH, Blansjaar BA. Predictors for the efficacy of electroconvulsive therapy: chart review of a naturalistic study. July 894–899
Kim CY, Shin Y-W, Joo YH, Hong J-P, Lee GH, Choi S-K. Risperidone dosing pattern and clinical outcome in psychosis: an analysis of 1713 cases. July 887–893
Kim DK see Koh KB
Kim SY see Koh KB
Kimata H. Differential modulation of cerebrospinal fluid neurotrophins in patients with atopic dermatitis who attempted suicide [letter]. Sept 1193–1194
Kingsbury SJ see Simpson GM
Kinnear CJ see Lochner C
Kinrys G see Papakostas GI
Kirov G, Tredget J, Dunn E, Moskvina V, Beer R, Khalid N. Underpowered repetitive transcranial magnetic stimulation might not be an effective antidepressant treatment [letter with reply]. Apr 543–544
Kirshner HS. Review of Yudofsky SC, Kim HF (eds): *Neuropsychiatric Assessment.* Dec 1617–1618
Kissling W see Rummel CB
Kitzman HJ see Chaudron LH
Kivlahan DR see Shores MM
Klein DF see Quitkin FM
Knapp RG see Brawman-Mintzer O
Knoll G see Silver H
Knowles JA see Lochner C
Koch WH see de Leon J
Koerselman F. Reply to Kirov G: Underpowered repetitive transcranial magnetic stimulation might not be an effective antidepressant treatment [letter]. Apr 543–544
Koh KB, Kim DK, Kim SY, Park JK. Relation between anger expression, depression, and somatic symptoms in depressive disorders and somatoform disorders. Apr 485–491
Koike R see Oda K
Konarski JZ see McIntyre RS
Konas S see Hermesh H
Kopasz M see Hornyak M
Koponen HJ see Saari KM
Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. Mar 353–357
Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Apr 515–520
Koran LM see Bogan AM
Koren G see McKenna K
Korf BR see Finn CT
Koskelainen P see Tiihonen J
Koskinen J see Lauronen E
Kostic D see Volavka J
Kozarić-Kovačić D, Pivac N, Mück-Šeler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. July 922–927
Kramer M. Review of Ahles SR: *Our Inner World: A Guide to Psychodynamics and Psychotherapy.* July 955
Kramer ML see Gopal S
Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Dec 1565–1569
Krystal JH see Pittenger C
Kuhn A see Ball SG
Kuhn EM see Bentler SE
Kumar A see Lavretsky H
Kuo C-J, Tsai S-Y, Lo C-H, Wang Y-P, Chen C-C. Risk factors for completed suicide in schizophrenia. May 579–585
Kuo C-J see Tsai S-Y
Kupfer DJ see Karp JF
Kupka R see Post RM
Kupka RW see McElroy SL
Kuskowski MA see Dailey LF
Kwentus J see Greenspan A
Kwon A see Wilens TE
Labad J, Menchón JM, Alonso P, Segalàs C, Jiménez S, Vallejo J. Female reproductive cycle and obsessive-compulsive disorder. Apr 428–435
Lai M see Ravaldi C
Lam W see Sir A
Lambert M see Schimmelmann BG
Lamberti JS, Costea GO, Olson D, Crilly JF, Maharaj K, Tu X, Groman A, Dietz MB, Bushey MP, Olivares T, Wiener K. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. July 900–906
Landa E see Dossenbach M
Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. Jan 100–106
Landi F see Onder G
Landtblom A-M see Murray V
Lang AE see Voon V
Langer S see Wingen M
Lankford A see Zemlan FP
Laor N see Toren P
Lapane KL see Liperoti R
Lara DR see Brunstein MG
Larsen JP see Aarsland D
Laurén LH see Saari KM
Lauronen E, Koskinen J, Veijola J, Miettunen J, Jones PB, Fenton WS, Isohanni M. Recovery from schizophrenic psychoses within the Northern Finland 1966 Birth Cohort. Mar 375–383
Lavretsky H, Roybal DJ, Ballmaier M, Toga AW, Kumar A. Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. Aug 964–967
Leadbetter J see Dossenbach M
Lecube A see Benabarre A
Lee C see Anand A
Lee C-H see Tsai S-Y
Lee GH see Kim CY
Lemelin S see Villeneuve E
LeNoci F see Marchiaro L
Leon AC see Nelson JC; Solomon DA
Lepkifker E. Reply to Shammi C: Single versus multiple daily dosing of lithium: renal effects [letter]. Mar 399
Lepkifker E. Reply to Smith EG: Lithium dosing schedule and renal insufficiency [letter]. Mar 397–398

Leppämäki S see Valtonen H
Lerner V, Miodownik C, Kaptsan A, Vishne T, Sela B-A, Levine J. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. Dec 1559–1564
Lerner V see Bergman J
Leskelä US see Melartin TK
Lestelä-Mielonen PS see Melartin TK
Leuchter AF see Morgan ML
Leverich GS see McElroy SL; Post RM
Levine J see Citrome L; Lerner V
Levine MD see Kalarchian MA
Levinson A see McKenna K
Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM Jr, Baxter LR Jr. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. June 736–743
Lieberman JA see Kraus JE
Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. Randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Feb 238–247
Liggin JDM see Brown ES
Lightfoot J see Anand A
Lim S. Reply to DeQuardo JR: Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter]. Mar 396
Lin H see Freeman EW
Lindeman SM see Saari KM
Lindenmayer J-P, Eerdekens E, Eerdekens M. Reply to Pinninti NR: Injection site pain with long-acting risperidone [letter]. May 657
Lindenmayer J-P see Citrome L
Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, Bernabei R. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Sept 1090–1096
Liperoti R see Onder G
Lisanby SH see Nahas Z
Lo C-H see Kuo C-J
Lochner C, Kinnear CJ, Hemmings SMJ, Seller C, Niehaus DJH, Knowles JA, Daniels W, Moolman-Smook JC, Seedat S, Stein DJ. Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. Sept 1155–1160
Loft H see Montgomery SA
Lomax JW. Review of Ursano RJ, Sonnenberg SM, Lazar SG: *Concise Guide to Psychodynamic Psychotherapy: Principles and Techniques of Brief, Intermittent, and Long-Term Psychodynamic Psychotherapy, 3rd ed.* Aug 1078
Londino DL see Rausch JL
Longo P see Marchiaro L
Loraas E see DeBattista C
Louie PM see Henderson DC
Loza N see Simpson GM
Lucca A see Rossini D
Luckenbaugh DA see Post RM
Lundmark J see Murray V
Luther JF see Perlis RH
Lütjohann D see Papassotiropoulos A
Lysaker PH, Davis LW, Gatton MJ, Herman SM. Associations of anxiety-related symptoms with reported history of childhood sexual abuse in schizophrenia spectrum disorders. Oct 1279–1284
Macey H see Moreno FA
Mack JE see Reeves RR
Mackin P. Weight gain and antipsychotics [letter with reply]. July 950–951
Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. Nov 1386–1391
Madrigal M see Saiz-Ruiz J
Magee C see Shedlack KJ
Mago R see Pinninti NR
Magri L see Rossini D
Mahadi S see Trivedi MH
Maharaj K see Lamberti JS
Mahmoud R see Brar JS
Mahorney SL see McKee JR
Malaya L see Galynker I
Mallinckrodt CH see Delgado PL
Mamdani M see Shulman KI
Manev R see Novick JS
Mangano RM see Liebowitz MR
Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N. Assessing demoralization and depression in the setting of medical disease. Mar 391–394
Mantere O see Valtonen H
Marangell LB see Nahas Z
Marchiaro L, Rocca P, LeNoci F, Longo P, Montemagni C, Rigazzi C, Bogetto F. Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. Nov 1423–1431
Marchiaro L see Rocca P
Marcus MD see Kalarchian MA
Marcus R see Volavka J
Marder SR see Erhart SM; Glick ID
Marom S see Hermesh H
Mårtensson B see Murray V
Martin AJ see Sir A
Martinez JM see Nahas Z
Maruyama M see Iwasaki K
Masramon X see Saiz-Ruiz J
Matar MA see Kaplan Z
Mathis F see Rocca P
Mathiske-Schmidt K see Baethge C
Matsumoto AM see Shores MM
Matsushima E see Oda K
Matthews AM. Review of Kadison RD, DiGeronimo TF: *College of the Overwhelmed: The Campus Mental Health Crisis and What to Do About It.* Apr 545
Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Nov 1432–1440
May RS see Li X
Mayleben DW see Zemlan FP
McClendon J. Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety [letter with reply]. Nov 1494–1495
McCracken JT. Safety issues with drug therapies for autism spectrum disorders. Suppl 10, 32–37
McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. Suppl 10, 9–18
McElroy SL, Suppes T, Keck PE Jr, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS, Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. May 617–624
McElroy SL see Keck PE Jr; Post RM
McGlinchey JB see Zimmerman M
McGorry PD see Schimmelmann BG
McGrath PJ see Quitkin FM; Taylor BP
McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. Suppl 3, 28–36
McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. Sept 1161–1168
McKeith IG see Aarsland D
McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. Apr 444–449
McKinney WT. Review of Charney DS (ed): *Molecular Neurobiology for the Clinician.* Aug 1080–1081
McKinnon K see Cournos F
McNamara RK see Delgado PL
McQuade RD see Volavka J
Mehtonen O-P see Tiihonen J
Meier A see Cohrs S
Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Sokero TP, Isometsä ET. Continuity is the main challenge in treating major depressive disorder in psychiatric care. Feb 220–227
Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. June 761–767
Meltzer HY. Commentary: suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. Apr 530–533
Meltzer HY see Yağcıoğlu AEA
Menard W see Grant JE; Phillips KA
Menaster M. Use of olanzapine in anorexia nervosa [letter with reply]. May 654–655
Menaster MJ. Weight gain, sexual dysfunction, and bupropion [letter with reply]. Oct 1335–1336
Menchón JM see Labad J
Mendelson WB. Review of the evidence for the efficacy and safety of trazodone in insomnia. Apr 469–476
Mendhekar DN. Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child [letter]. Dec 1616
Mesters P see Demyttenaere K
Meyer S see Sevy S
Meyers A see Hoffmann VP
Mian A, Santos CW. Review of Dulcan MK, Martini R, Lake MB: *Concise Guide to Child and Adolescent Psychiatry, Third Edition.* June 806–807

Michelson D see Adler LA
Miettunen J see Lauronen E
Milis L see Misri S
Miller AH see Raison CL
Miller DE, Sebastian CS. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report [letter]. Feb 269–270
Miller MC. Review of Petit JR: *Handbook of Emergency Psychiatry*. Mar 402–403
Miller S see Rausch JL
Milosavljevic N see Carpenter LL
Milton DR see Adler LA
Mintz J see Erhart SM
Miodownik C see Lerner V
Mirandola M see Guaiana G
Mirza N see Huey ED
Misawa F, Fujii Y. Reply to Cohen: Diabetes mellitus during olanzapine and quetiapine treatment in Japan [letter]. Feb 266–267
Mischoulon D see Iosifescu DV
Misri S, Reebye P, Corral M, Milis L. Reply to McClendon J: Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety [letter]. Nov 1495
Mitton M see Thase ME
Miyasaka N see Oda K
Moceri VM see Shores MM
Modai I see Silver H
Modell JG see Thase ME
Modestin J, Pian DD, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. Apr 534–538
Molyva D see Papassotiropoulos A
Monma Y see Iwasaki K
Montemagni C see Marchiaro L
Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger J-P. 24-Week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Oct 1270–1278
Moolman-Smook JC see Lochner C
Moore CW see Simon NM
Moore DJ see Jeste ND
Moore H see Wilens TE
Moore RJ see Adler LA
Mor V see Liperoti R
Morais SL see Chaves MPR
Moreno FA, Macey H, Schreiber B. Carnitine levels in valproic acid–treated psychiatric patients: a cross-sectional study. May 555–558
Morgan MI, Cook IA, Rapkin AJ, Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. June 774–780
Morris DW see Trivedi MH
Morris MC see Wilens TE
Morrow S see Chaudron LH
Moskvina V see Kirov G
Moulis M see Wu EQ
Mück-Šeler D see Kozarić-Kovačić D
Mueller TI see Solomon DA
Mulchahey JJ see Zemlan FP
Mullen J see Bowden CL
Müller-Oerlinghausen B see Baethge C
Mulsant BH see Dombrovski AY
Murata Y see Oda K
Muriel AC see Simon NM
Murray V, von Arbin M, Bartfai A, Berggren A-L, Landtblom A-M, Lundmark J, Näsman P, Olsson J-E, Samuelsson M, Terént A, Varelius R, Åsberg M, Mårtensson B. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. June 708–716
Murthy P see Chand PK
Musch W see Verhoeven A
Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, Martinez JM, George MS. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. Sept 1097–1104
Näsman P see Murray V
Nasrallah HA. Neurologic comorbidities in schizophrenia. Suppl 6, 34–46
Nasrallah HA. Overview of common medical comorbidities in patients with schizophrenia. Suppl 6, 3–4
Nelson D see Simeon D
Nelson JC. Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? [ASCP Corner] Aug 1071
Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. Nov 1409–1414
Nemeroff CB. Introduction. Suppl 8, 3–4
Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. Suppl 8, 13–21
Nemeroff CB, Vale WW. Neurobiology of depression: inroads to treatment and new drug discovery. Suppl 7, 5–13
Nemeroff CB, Wagner KD. Introduction. Developmental neurobiology and psychiatry: challenges and best practices for studies in children and adolescents. Suppl 7, 3–4
Nemeroff CB see Raison CL; Simon JS
Nemets B, Bersudsky Y, Belmaker RH. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. May 586–590
Nemoto M see Iwasaki K
Neumann A-C see Cohrs S
Newman MC see Chaudron LH
Nguyen DD see Henderson DC
Niehaus DJH see Lochner C
Nierenberg AA see Hollon SD; Iosifescu DV; Novick JS; Papakostas GI; Simon NM; Weiss RD
Nietert PJ see Brawman-Mintzer O
Nil R see Montgomery SA
Ninan PT, Dunlop BW. Neurobiology and etiology of panic disorder. Suppl 4, 3–7
Nitsch RM see Papassotiropoulos A
Nolen WA see McElroy SL; Post RM
Novick JS, Stewart JW, Wisniewski SR, Cook IA, Manev R, Nierenberg AA, Rosenbaum JF, Shores-Wilson K, Balasubramani GK, Biggs MM, Zisook S, Rush AJ, for the STAR*D Investigators. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Aug 1002–1011
Novins DK see Gnanadesikan M
Nowakowska C see Ketter TA
Nurnberger JI Jr see Anand A
O'Brien CP. Benzodiazepine use, abuse, and dependence. Suppl 2, 28–33
O'Brien JT see Aarsland D
O'Connor CM, Glassman AH, Harrison DJ. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Mar 346–352
Oda K, Matsushima E, Okubo Y, Ohta K, Murata Y, Koike R, Miyasaka N, Kato M. Abnormal regional cerebral blood flow in systemic lupus erythematosus patients with psychiatric symptoms. July 907–913
Ohta K see Oda K
O'Keeffe CM see Ketter TA
Oksanen J see Tiihonen J
Okubo Y see Oda K
Olfson M, Uttaro T, Carson WH, Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. Mar 331–338
Olfson M, Uttaro T, Carson WH, Tafesse E. Reply to Rico-Villademoros: Antipsychotic-induced sexual dysfunction and the strength of the evidence [letter]. Aug 1075–1076
Olivares T see Lamberti JS
Olsen MK see Gopal S
Olson D see Lamberti JS
Olsson J-E see Murray V
Onder G, Landi F, Gambassi G, Liperoti R, Soldato M, Catananti C, Finne-Soveri H, Katona C, Carpenter I, Bernabei R. Association between pain and depression among older adults in Europe: results from the Aged in Home Care (AdHOC) project: a cross-sectional study. Aug 982–988
Ondrasik J see Pollack MH
O'Reardon JP, Blumner KH, Peshek AD, Pradilla RR, Pimiento PC. Long-term maintenance therapy for major depressive disorder with rTMS. Dec 1525–1529
Ornoy A see Diav-Citrin O
Ornoy S see Diav-Citrin O
Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. June 726–729
Ostacher MJ see Weiss RD
Otto MW, Bruce SE, Deckersbach T. Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need. Suppl 2, 34–38
Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. Suppl 4, 28–32
Otto MW see Weiss RD
Ottolini F see Mangelli L
Overman GP see Huey ED
Pagano ME see Grant JE
Pan R-M see de Leon J
Pandina G see Brar JS
Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ III, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Oct 1326–1330

Papakostas GI see Iosifescu DV
Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lütjohann D, Nitsch RM, Hock C. Cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. July 940–947
Paradiso E see Bellino S
Park JK see Koh KB
Patterson TL see Jeste ND
Paulson GW. Historical comments on tardive dyskinesia: a neurologist's perspective. Feb 260–264
Paulsson B see Bowden CL
Paxil CR Panic Disorder Study Group see Sheehan DV
Payne VM see Connor KM
Pedone C see Liperoti R
Peifer KL see Chaudron LH
Peindl KS see Gracious BL
Pepplinkhuizen L see van Riemsdijk MM
Perel JM see Gracious BL
Perera P see Roy-Byrne PP; Sheehan DV
Perez LM see Chaudron LH
Perez-Rodriguez MM see Diaz-Sastre C
Perla JM see Suppes T
Perlis RH. Role of pharmacologic treatment guidelines for bipolar disorder. Suppl 3, 37–47
Perlis RH, Fava M, Rush AJ. Reply to Benazzi: Possible bipolar nature of irritability in major depressive disorder [letter]. Aug 1073
Perlis RH, Fraguas R, Fava M, Trivedi MH, Luther JF, Wisniewski SR, Rush AJ. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Feb 159–166
Perlis RH, Keck PE Jr. Texas implementation of medication algorithms update for treatment of bipolar I disorder [commentary]. July 818–820
Perlis RH see Iosifescu DV
Perlman CA see Simon NM
Perry EK see Aarsland D
Perry R see Aarsland D
Peshek AD see O'Reardon JP
Petersen TJ see Papakostas GI
Petrides G see Barnas ME
Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. May 564–574
Petti TA. Review of Casey BJ (ed): *Developmental Psychobiology*. Sept 1196
Phillips KA, Coles ME, Menard W, Yen S, Fay C, Weisberg RB. Suicidal ideation and suicide attempts in body dysmorphic disorder. June 717–725
Phillips KA see Grant JE
Pian DD see Modestin J
Pies R see Cohen ST
Pimiento PC see O'Reardon JP
Pinkofsky HB, Hahn AM, Campbell FA, Rueda J, Daley DC, Douaihy AB. Reduction of opioid-withdrawal symptoms with quetiapine. Oct 1285–1288
Pinninti NR, Mago R. Injection site pain with long-acting risperidone [letter with reply]. May 656–657
Pitschel-Walz G see Rummel CB
Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder [letter]. Nov 1492–1493
Pitts CD see Roy-Byrne PP
Pivac N see Kozarić-Kovačić D
Plana MT see Benabarre A
Podolski A see Wilens TE
Poirier J see DeBattista C
Pollack MH. Comorbid anxiety and depression. Suppl 8, 22–29
Pollack MH. Pharmacotherapy of panic disorder. Suppl 4, 23–27
Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. Selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. Nov 1401–1408
Pollack MH see Simon NM; Stevens JC; Weiss RD
Pontiggia A see Benedetti F
Popova E see Vieta E
Porcelli P see Mangelli L
Portera L see Nelson JC
Posey DJ see McDougle CJ
Post RM. Impact of bipolar depression. Suppl 5, 5–10
Post RM, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Leverich GS, Kupka R, Nolen WA, Luckenbaugh DA, Walden J, Grunze H. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. Mar 370–374
Post RM see McElroy SL; Yatham LN
Posternak MA, Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. June 705–707
Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? a meta-analysis. Feb 148–158
Posternak MA, Zimmerman M. Reply to Quitkin: Accurate meta-analytical assessment of "true antidepressant effects" needed [letter]. Sept 1192–1193
Posternak MA see Coccaro EF; Solomon DA; Zimmerman M
Pradilla RR see O'Reardon JP
Price LH see Carpenter LL
Prudic J see Dombrovski AY
Puck M see Tiihonen J
Putkonen H see Tiihonen J
Qin L see Kalarchian MA
Quitkin FM, McGrath PJ, Stewart JW, Deliyannides D, Taylor BP, Davies CA, Klein DF. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. June 670–676
Quitkin FM, McGrath PJ, Stewart JW, Klein DF, Ross DC. Accurate meta-analytical assessment of "true antidepressant effects" needed [letter with reply]. Sept 1192
Quitkin FM see Taylor BP
Racette SR see Finn CT
Rack MJ. Review of Neubauer DN: *Understanding Sleeplessness: Perspective on Insomnia*. June 806
Rady A see Simpson GM
Rafanelli C see Fava GA; Mangelli L
Raghunandanan S see Shetti CN
Rahman S see Zimmerman M
Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. Jan 41–48
Rajagopalan KS see Matza LS
Ramaekers JG see Wingen M
Ramirez PM see Garno JL
Ramos FLP see Brunstein MG
Rao NR. Review of Andrews LB, Burruss JW: *Core Competencies for Psychiatric Education: Defining, Teaching, and Assessing Resident Competence*. July 953–954
Rapkin AJ see Morgan ML
Ratner S see Toren P
Rausch JL, Sirota EL, Londino DL, Johnson ME, Carr BM, Bhatia R, Miller S. Open-label risperidone for Asperger's disorder: negative symptom spectrum response. Dec 1593–1598
Ravaldi C, Barboni E, Lai M, Rotella CM, Vannacci A, Ricca V. Obesity and mood disorders: the complex problem of insight [letter]. Feb 265
Reddy YCJ, D'Souza SM, Shetti C, Kandavel T, Deshpande S, Badamath S, Singisetti S. 11- to 13-year follow-up of 75 subjects with obsessive-compulsive disorder. June 744–749
Reddy YCJ see Shetti CN
Reebye P see Misri S
Reeve E see Bhatti MA
Reeves RR, Mack JE. Allergic reaction to depot risperidone but not to oral risperidone [letter]. July 949
Reiman EM. Focus on Alzheimer's disease and related disorders [editorial]. July 816–817
Reiman EM. In this issue: genetics, cholesterol, and the risk of Alzheimer's disease. July 938–939
Rendon DM see de Leon J
Repo-Tiihonen E see Tiihonen J
Reviere R see Kraus JE
Reynolds CF III see Karp JF
Ricca V see Ravaldi C
Richard N see Thase ME
Richardson GS. Human circadian system in normal and disordered sleep. Suppl 9, 3–9
Rickels K see Pollack MH
Rico-Villademoros F, Calandre EP. Antipsychotic-induced sexual dysfunction and the strength of the evidence [letter with reply]. Aug 1074–1075
Riemann D see Hornyak M
Rigatelli M see Mangelli L
Rigazzi C see Marchiaro L
Rigotti NA see Evins AE
Riley-Lazo KP see Rosenlicht NZ
Risby ED. Review of Ursano RJ, Norwood AE (eds): *Trauma & Disaster: Responses & Management*. Mar 402
Ritchie K see Tsuno N

Ritzler BA see Garno JL
Rivoira E see Rocca P
Rocca P, Calvarese P, Faggiano F, Marchiaro L, Mathis F, Rivoira E, Taricco B, Bogetto F. Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. Mar 360–369
Rocca P see Marchiaro L
Roche-Desilets J see Zacher JL
Rochon P see Shulman KI
Rockett CB see Thase ME
Rodenbeck A see Cohrs S
Ros S see Vieta E
Rosenbaum JF. Attitudes toward benzodiazepines over the years. Suppl 2, 4–8
Rosenbaum JF see Novick JS
Rosenberg R see Zemlan FP
Rosenheck R see Sernyak MJ
Rosenlicht NZ, Riley-Lazo KP. Interactions of cyclobenzaprine and tricyclic antidepressants [letter]. Jan 134–135
Rosenthal MH see Sevy S
Ross DC see Quitkin FM
Rossini D, Magri L, Lucca A, Giordani S, Smeraldi E, Zanardi R. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? a double-blind, randomized, sham-controlled trial. Dec 1570–1576
Rössler W see Hasler G
Rotella CM see Ravaldi C
Roth T. Prevalence, associated risks, and treatment patterns of insomnia. Suppl 9, 10–13
Rothbaum BO see Kozarić-Kovačić D
Rothschild AJ. Placebo response in psychotic depression [letter with reply]. Dec 1615
Roybal DJ see Lavretsky H
Roy-Byrne PP. GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. Suppl 2, 14–20
Roy-Byrne PP, Perera P, Pitts CD, Christi JA. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. Oct 1228–1233
Roy-Byrne PP, Wagner AW, Schraufnagel TJ. Understanding and treating panic disorder in the primary care setting. Suppl 4, 16–22
Roy-Byrne PP see Pollack MH
Ruan WJ see Grant BF
Rueda J see Pinkofsky HB
Ruini C see Fava GA
Ruiz P. Review of Coombs RH (ed.): *Handbook of Addictive Disorders: A Practical Guide to Diagnosis and Treatment*. June 804
Rulf D see Cohen ST
Rummel CB, Hansen W-P, Helbig A, Pitschel-Walz G, Kissling W. Peer-to-peer psychoeducation in schizophrenia: a new approach. Dec 1581–1586
Rush AJ see Byerly MJ; Hollon SD; Nahas Z; Novick JS; Perlis RH
Rüther E see Cohrs S
Ryan JL see Iosifescu DV
Ryan ND see Barbe RP; Emslie GJ
Rytsälä HJ see Melartin TK
Ryynänen O-P see Tiihonen J
Saari ĶM, Lindeman SM, Viilo KM, Isohanni MK, Järvelin M-R, Laurén LH, Savolainen MJ, Koponen HJ. 4-Fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. May 559–563
Sachs GS see Suppes T; Weiss RD
Sackeim HA see Dombrovski AY; Nahas Z
Sacks FM see Goff DC
Sadan T see Kaplan Z
Saha TD see Grant BF
Saiz-Ruiz J, Blanco C, Ibáñez A, Masramon X, Gómez MM, Madrigal M, Díez T. Sertraline treatment of pathological gambling: a pilot study. Jan 28–33
Saiz Ruiz J see Diaz-Sastre C
Saleh FM. Issues to consider in the assessment and treatment of paraphilic patients [letter with reply]. June 802–803
Salloum IM see Weiss RD
Salmon MP see Abel KM
Salomon RM. Review of Daruna JH: *Introduction to Psychoneuroimmunology*. Nov 1496
Salomon RM. Review of Meck WH (ed): *Functional and Neural Mechanisms of Interval Timing*. Aug 1078–1079
Salzman C. Review of Bowers M Jr: *Abetting Madness: The Role of Illicit and Prescribed Drugs in Promoting Psychotic and Manic Disorders*. June 807
Salzman C. Review of van Praag HM, de Kloet R, van Os J: *Stress, the Brain and Depression*. July 954
Sammel MD see Freeman EW
Samuelsson M see Murray V
Sánchez-Barranco P. New onset of diabetes mellitus with ziprasidone: a case report [letter]. Feb 268–269
Sánchez-Moreno J see Vieta E
Sangeleer M see Demyttenaere K
Sanger TM see Shelton RC
Santos CW see Milan A
Sar V see Karadag F
Sasaki H see Iwasaki K
Satoh-Nakagawa T see Iwasaki K
Savolainen MJ see Saari KM
Saxena K, Silverman MA, Chang K, Khanzode L, Steiner H. Baseline predictors of response to divalproex in conduct disorder. Dec 1542–1549
Scahill L. Diagnosis and evaluation of pervasive developmental disorders. Suppl 10, 19–25
Schaefer C see Diav-Citrin O
Scharf MB see Zemlan FP
Schecter JM see Carpenter LL
Schimmelmann BG, Conus P, Edwards J, McGorry PD, Lambert M. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. Oct 1239–1246
Schmeidler J see Simeon D
Schoenfeld DA see Evins AE
Schooler NR see Sevy S
Schraufnagel TJ see Roy-Byrne PP
Schreiber B see Moreno FA
Schuh L see Hoffmann VP
Schumacher MR see Ketter TA
Schutters SIJ, van Megen HJGM, Westenberg HGM. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [letter]. Apr 540–542
Scott J see Karp JF
Scott M see Wilens TE
Sebastian CS see Miller DE
Seedat S see Lochner C
Segalàs C see Labad J
Seki T see Iwasaki K
Sela B-A see Lerner V
Seller C see Lochner C
Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. Nov 1463–1467
Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswaraiah H, Gunduz-Bruce H, Schooler NR. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. July 839–843
Shakir S see McKenna K
Shammi C. Single versus multiple daily dosing of lithium: renal effects [letter with reply]. Mar 398–399
Sharpe J-K, Stedman TJ, Byrne NM, Hills AP. Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain [letter with reply]. July 951–952
Sharpley AL, Attenburrow MEJ, Hafizi S, Cowen PJ. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. Apr 450–454
Shear MK see Simon NM
Shechtman S see Diav-Citrin O
Shedlack KJ, Hennen J, Magee C, Cheron DM. Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and comorbid psychiatric disorders. Jan 52–62
Sheehan DV, Burnham DB, Iyengar MK, Perera P, for the Paxil CR Panic Disorder Study Group. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Jan 34–40
Sheitman BB see Kraus JE
Shekhar A see Anand A; Ball SG
Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Oct 1289–1297
Shetti C see Reddy YCJ
Shetti CN, Reddy YCJ, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU-F, Raghunandanan S. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. Dec 1518–1524
Shi L see Wu EQ
Shiloh R see Hermesh H
Shin Y-W see Kim CY
Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. Jan 7–14
Shores-Wilson K see Novick JS
Shulman KI, Sykora K, Gill S, Mamdani M, Bronskill S, Wodchis WP, Anderson G, Rochon P. Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. Apr 424–427
Shults KS see Hoffmann VP

Siddequehusen MU-F see Shetti CN
Silver H, Goodman C, Knoll G, Isakov V, Modai I. Schizophrenia patients with a history of severe violence differ from nonviolent schizophrenia patients in perception of emotions but not cognitive function. Mar 300–308
Silverman MA see Saxena K
Simeon D, Greenberg J, Nelson D, Schmeidler J, Hollander E. Dissociation and posttraumatic stress 1 year after the World Trade Center disaster: follow-up of a longitudinal survey. Feb 231–237
Simon A see Hirschowitz J
Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. Oct 1216–1220
Simon NM, Fischmann D. Implications of medical and psychiatric comorbidity with panic disorder. Suppl 4, 8–15
Simon NM, Pollack MH, Fischmann D, Perlman CA, Muriel AC, Moore CW, Nierenberg AA, Shear MK. Complicated grief and its correlates in patients with bipolar disorder. Sept 1105–1110
Simon NM see Weiss RD
Simpson GM, El Sheshai A, Loza N, Kingsbury SJ, Fayek M, Rady A, Fawzy W. 8-Week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. May 598–602
Simpson GM, Kingsbury SJ. Reply to Rothschild AJ: Placebo response in psychotic depression [letter]. Dec 1615–1616
Sinclair J see Hawton K
Singer S see Zimmerman M
Singisetti S see Reddy YCJ; Shetti CN
Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Oct 1312–1320
Sirota EL see Rausch JL
Sklar P see Finn CT
Sloan KL see Shores MM
Slooff CJ see Tenback DE
Smeraldi E see Benedetti F; Rossini D
Smith EG. Lithium dosing schedule and renal insufficiency [letter with reply]. Mar 396–397
Smith EH see Koran LM
Smith S see Grant BF
Smoller JW see Finn CT
Snyder H see Pollack MH
SOHO Study Group see Tenback DE
Sokero TP see Melartin TK
Soldato M see Onder G
Solomon DA. Reply to Jefferson: It looks like "bradyphylaxis" to me [letter]. Aug 1076–1077
Solomon DA, Leon AC, Mueller TI, Coryell W, Teres JJ, Posternak MA, Judd LL, Endicott J, Keller MB. Tachyphylaxis in unipolar major depressive disorder. Mar 283–290
Solomon Z, Dekel R. Posttraumatic stress disorder among Israeli ex–prisoners of war 18 and 30 years after release. Aug 1031–1037
Solvason B see DeBattista C
Sondheimer SJ see Freeman EW
Sonino N see Fava GA; Mangelli L
Sorio A see Guaiana G
SPD417 Study Group see Weisler RH
Spencer TJ see Adler LA; Wilens TE
Spicer SS. Hurricane Katrina: a physician's whirlwind course in disaster psychiatry [commentary]. Nov 1349–1350
Stahl SM. Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder? [BRAINSTORMS] Jan 5–6
STAR*D Investigators see Novick JS
Stedman TJ see Sharpe J-K
Steffens DC see Gopal S
Stein DJ see Lochner C
Steiner H see Findling RL; Saxena K
STEP-BD Investigators see Weiss RD
Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. Suppl 2, 21–27
Stewart JW see Quitkin FM; Novick JS; Taylor BP
Stewart SA. Effects of benzodiazepines on cognition. Suppl 2, 9–13
Stewart SE, Jenike MA, Keuthen NJ. Severe obsessive-compulsive disorder with and without comorbid hair pulling: comparisons and clinical implications. July 864–869
Stigler KA see McDougle CJ
Stinson FS see Compton WM; Grant BF; Petry NM
Stolk RP see Cohen D
Strakowski SM see Fleck DE
Streltzer J. Review of Trimble M: *Somatoform Disorders: A Medicolegal Guide.* Aug 1081
Stricker BHCh see van Riemsdijk MM
Sturkenboom MCJM see van Riemsdijk MM
Su K-P see Chiu C-C
Su T-P, Huang C-C, Wei I-H. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. July 930–937
Subuh Surja AA, Brotzge KE, El-Mallakh RS. Serious rash with lamotrigine after carbamazepine discontinuation: a case report [letter]. Mar 400–401
Sullivan G see Cournos F
Sunderland T see Huey ED
Suominen K see Valtonen H
Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, . Crismon ML, Ketter TA, Sachs GS, Swann AC, for the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. July 870–886
Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. Suppl 5, 11–16
Suppes T see McElroy SL; Post RM; Yatham LN
Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Feb 167–173
Susce MT see de Leon J
Sutton L see Hawton K
Svensson K see Bowden CL
Swann AC. Long-term treatment in bipolar disorder. Suppl 1, 7–12
Swann AC see Suppes T; Weisler RH
Swope DM see Chen JJ
Sykora K see Shulman KI
Szabo ST see Blier P
Tafesse E see Olfson M
Takala P see Tiihonen J
Tamar-Gurol D see Karadag F
Tanguay PE. Review of Ozonoff S, Rogers SJ, Hendren RL (eds): *Autism Spectrum Disorders: A Research Review for Practitioners.* Feb 271–272
Tanji H see Iwasaki K
Taricco B see Rocca P
Taylor BP, Quitkin FM, McGrath PJ, Stewart JW. Do antihypertensives make tranylcypromine safer? three case reports [letter]. May 657–658
Taylor BP see Quitkin FM
Ten A see Galynker I
Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, and the SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Sept 1130–1133
Tenneij NH, van Megen HJGM, Denys DAJP, Westenberg HGM. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. Sept 1169–1175
Terént A see Murray V
Teres JJ see Solomon DA
Tetelbaum M see McKenna K
Teunisse RJ. Problems in assessing musical hallucinations [letter with reply]. Jan 136
Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder see Suppes T
Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Aug 974–981
Thase ME see Fava M; Hollon SD; Landén M; Weiss RD
Thienhaus OJ. Review of Martensen RL: *The Brain Takes Shape: An Early History.* Aug 1079–1080
Thompson CL see Matza LS
Thompson JW. Cultural competence in clinical psychopharmacology [ASCP CORNER]. June 799
Thongy T see Zimmerman M
Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvärinen S, Eronen M, Putkonen H, Takala P, Mehtonen O-P, Puck M, Oksanen J, Koskelainen P, Joffe G, Aer J, Hallikainen T, Ryynänen O-P, Tupala E. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Aug 1012–1015
Tillman R see Geller B

Toga AW see Lavretsky H
Tohen M see Keck PE Jr
Tolbert LC see Li X
Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. Dec 1550–1558
Tollefson GD see Shelton RC
Tomita N see Iwasaki K
Toren P, Weizman A, Ratner S, Cohen D, Laor N. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. Apr 499–503
Tornatore FL. Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia [letter with reply]. Nov 1493–1494
Townsend SW see Dailey LF
Tran PV see Delgado PL
Tredget J see Kirov G
Treuer T, Basson BR. Is there a real difference between the first onset of efficacy for atypical antipsychotic monotherapies in acute bipolar mania? [letter with reply] Oct 1333–1334
Trivedi M see Hollon SD
Trivedi MH, Morris DW, Grannemann BD, Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. Aug 1064–1070
Trivedi MH see Perlis RH
Tsai S-Y, Lee C-H, Kuo C-J, Chen C-C. Retrospective analysis of risk and protective factors for natural death in bipolar disorder. Dec 1587–1592
Tsai S-Y see Kuo C-J
Tsolaki M see Papassotiropoulos A
Tsuno N, Besset A, Ritchie K. Sleep and depression. Oct 1254–1269
Tu X see Lamberti JS
Tümüklü M see Yağcıoğlu AEA
Tunca Z see Yağcıoğlu AEA
Tune LE see Greco KE
Tupala E see Tiihonen J
Turgut TI see Yağcıoğlu AEA
Turkoz I see Brar JS
Tyrka AR see Carpenter LL
Uguz S see Sir A
Uttaro T see Olfson M
Uy KK see Zimmerman M
Vågerö M see Bowden CL
Vahip S see Sir A
Valdés M see Benabarre A
Vale WW see Nemeroff CB
Vallejo J see Labad J
Valtonen H, Suominen K, Mantere O, Leppämäki S, Arvilommi P, Isometsä ET. Suicidal ideation and attempts in bipolar I and II disorders. Nov 1456–1462
Van Ameringen M see Pollack MH
van Balkom AJLM see van Oppen P
Van Campen LE see Shelton RC
van Dyck R see van Oppen P
van Harten PN see Heck AH; Tenback DE
Van Horn WA see Greco KE
van Megen HJGM see Schutters SIJ; Tenneij NH
VanMeter S see Thase ME
Vannacci A see Ravaldi C
van Oppen P, van Balkom AJLM, de Haan E, van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. Nov 1415–1422
van Os J see Tenback DE
van Riemsdijk MM, Sturkenboom MCJM, Pepplinkhuizen L, Stricker BHCh. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. Feb 199–204
van Wattum PJ. Review of Bezchlibnyk-Butler KZ, Virani AS (eds): *Clinical Handbook of Psychotropic Drugs for Children and Adolescents.* Dec 1617
Vapnik T see Bogan AM
Varelius R see Murray V
Veijola J see Lauronen E
Velásquez DM see de Leon J
Verhoeven A, Musch W, Decaux G. Treatment of the polydipsia-hyponatremia syndrome with urea. Nov 1372–1375
Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. Suppl 1, 24–29
Vieta E. Package of care for patients with bipolar depression. Suppl 5, 34–39
Vieta E, Ros S, Goikolea JM, Benabarre A, Popova E, Comes M, Capapey J, Sánchez-Moreno J. Open-label study of amisulpride in the treatment of mania. May 575–578
Vieta E see Benabarre A; Yatham LN
Viilo KM see Saari KM
Villanueva N see Susce MT
Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. Oct 1298–1303
Villeneuve J see Alméras N
Vishne T see Lerner V
Visweswaraiah H see Sevy S
Voderholzer U see Hornyak M
Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, Hardy S, Marcus R. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. Nov 1362–1366
Volavka J see Citrome L
von Arbin M see Murray V
Voon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. Dec 1530–1535
Vulink NCC, Denys D, Westenberg HGM. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. Feb 228–230
Wagner AW see Roy-Byrne PP
Wagner KD see Emslie GJ; Nemeroff CB
Wahlbeck K see Tiihonen J
Walden J see McElroy SL; Post RM
Wall D see Ball SG
Wan MW see Abel KM
Wang F see Delgado PL
Wang PW see Ketter TA
Wang Q see Davidson JRT
Wang Y see Thase ME
Wang Y-P see Kuo C-J
Watkin JG see Delgado PL
Webb RT see Abel KM
Wedlund PJ see de Leon J
Wei I-H see Su T-P
Weisberg RB see Phillips KA
Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH, for the SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Mar 323–330. Correction, May 659
Weiss RD, Ostacher MJ, Otto MW, Calabrese JR, Fossey M, Wisniewski SR, Bowden CL, Nierenberg AA, Pollack MH, Salloum IM, Simon NM, Thase ME, Sachs GS, for STEP-BD Investigators. Does recovery from substance use disorder matter in patients with bipolar disorder? June 730–735
Weissfeld LA see Kalarchian MA
Weizman A see Hermesh H; Toren P
Weller EB see Findling RL
Wells LA. Review of Peteet JR: *Doing the Right Thing: An Approach to Moral Issues in Mental Health Treatment.* Aug 1079
Wells LA. Review of Tasman A, Kay J, Lieberman JA (eds): *Psychiatry, vols 1 and 2, 2nd ed.* July 954–955
Westenberg HGM see Schutters SIJ; Tenneij NH; Vulink NCC
White WD see Crockford DN
Wiener K see Lamberti JS
Wilcox MA see Finn CT
Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. Feb 253–259
Williamson DE see Barbe RP
Williamson DJ see Shelton RC
Wilton L see McKenna K
Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. Apr 436–443
Wisner KL see Gracious BL
Wisniewski SR see Novick JS; Perlis RH; Weiss RD
Wodchis WP see Shulman KI
Wollmer MA see Papassotiropoulos A
Woolwine BJ see Raison CL
Worthington JJ III see Papakostas GI
Wozniak J. Recognizing and managing bipolar disorder in children. Suppl 1, 18–23
Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. Economic burden of schizophrenia in the United States in 2002. Sept 1122–1129
Yağcıoğlu AEA, Akdede BBK, Turgut TI, Tümüklü M, Yazıcı MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A,

Tunca Z, Meltzer HY. Double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Jan 63–72
Yanowitch P see Galynker I
Yatham LN. Diagnosis and management of patients with bipolar II disorder. Suppl 1, 13–17
Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR. Atypical antipsychotics in bipolar depression: potential mechanisms of action. Suppl 5, 40–48
Yazıcı MK see Yağcıoğlu AEA
Yen S see Phillips KA
Young AH see Mackin P
Young AS see Erhart SM
Young EA see Coryell W
Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam [letter]. Dec 1614–1615
Zanardi R see Rossini D
Zander J see Bhatti MA
Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. Efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. Mar 384–390
Zhang W see Connor KM
Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Differences between minimally depressed patients who do and do not consider themselves to be in remission. Sept 1134–1138
Zimmerman M, Posternak MA, Attiullah N, Friedman M, Boland RJ, Baymiller S, Berlowitz SL, Rahman S, Uy KK, Singer S, Chelminski I. Why isn't bupropion the most frequently prescribed antidepressant? May 603–610
Zimmerman M, Posternak MA, Attiullah N, Friedman M, Boland RJ, Baymiller S, Berlowitz SL, Rahman S, Uy KK, Singer S, Chelminski I, Thongy T. Reply to Menaster MJ: Weight gain, sexual dysfunction, and bupropion [letter]. Oct 1336–1339
Zimmerman M see Coccaro EF; Posternak MA
Zipursky RB see McKenna K
Zisook S, Glick I, Goldberg DA. Challenges and opportunities in teaching psychopharmacology during residency training [ASCP CORNER]. July 948
Zisook S see Novick JS
Zuardi AW see Chaves MPR
Zwinderman AH see Kho KH

The Journal of Clinical Psychiatry

CALL FOR PAPERS

www.PSYCHIATRIST.com/authors/call.htm

FOCUS ON WOMEN'S MENTAL HEALTH

Awareness of the importance of biological sex and gender to health is increasing. Medical research that emphasizes the differences in prevalence, etiology, and course of illnesses between women and men over the life cycle generates valuable insights into prevention, diagnosis, and treatment.

In recognition of the need for increased gender-based research, the *Journal* invites submissions of randomized clinical trials of treatment interventions as well as well-designed, well-conducted studies of epidemiologic, biological, psychosocial, economic, and health services aspects of women's mental health issues.

Topics of interest include all aspects of mental health issues pertinent to the female reproductive lifespan, disorders that disproportionately affect women, and inquiries into how gender impacts the course and treatment of disorders that affect both women and men. All submitted manuscripts will undergo the *Journal's* usual editorial evaluation and peer review.

Our electronic submission system is easy to use and facilitates rapid turnaround. Please consult the *Journal's* Information for Authors for guidelines on manuscript preparation at www.psychiatrist.com/authors. Accepted articles will be published as part of our Focus on Women's Mental Health section.

THE JOURNAL OF CLINICAL PSYCHIATRY